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Abstract
Epithelial ovarian cancer (EOC) is the most lethal gynecological malignancy in the developed
world. EOC metastasis is unique since malignant cells detach directly from the primary tumor
site into the abdominal fluid and form multicellular aggregates, called spheroids, that possess
enhanced survival mechanisms while in suspension. As such, altered cell adhesion properties are
paramount to EOC metastasis with cell detachment from the primary tumor, dissemination as
spheroids, and reattachment to peritoneal surfaces for secondary tumor formation. that play a
crucial role in cell-cell and cell-extracellular matrix interactions, having implications in multiple
steps of cancer progression. We previously showed that the CRISPR-ablation of LKB1 or its
downstream effector NUAK1 resulted in spheroid disaggregation in vitro and is required for
efficient EOC metastasis in mouse tumor cell xenografts. Global gene expression analysis
demonstrated a coordinated reduction in 5-integrin (encoded by ITGβ5 gene). Integrins are a
family of cell-adhesion receptors required to mediate cellular interactions with the extracellular
matrix (ECM) and promote tumorigenesis in various malignancies; however, the role of 5integrin in EOC is unknown. Using publicly-available datasets and western blot analysis, we
identified relatively high 5 integrin expression in established and patient ascites-derived EOC
cell lines. siRNA-mediated knockdown of ITGβ5 reduced EOC cell adhesion, impacted adherent
cell and spheroid viability. We identified that 5 integrin is required for efficient spheroid
reattachment and subsequent cell spreading. When evaluating the interaction of 5 integrin with
ECM ligands, results indicate that 5 integrin and its association with vitronectin may play a role
in spheroid reattachment.
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Summary for lay Audience
Epithelial ovarian cancer is one of the most lethal gynaecological cancers in the developed world
and most individuals are diagnosed at advanced stages. When ovarian cancer cells spread, a
process called metastasis, the cancer cells try to survive starvation-like conditions by forming
cell clusters called spheroids. During this time, ovarian cancer cells change their cell adhesion
properties to allow them to survive and form more tumours. Our laboratory discovered that a
molecule called “Liver Kinase B1” (LKB1) and its downstream target, NUAK1, enables ovarian
cancer cells to survive these stressful conditions using different strategies to generate energy.
The loss of these two molecules leads to a decrease in a cell adhesion molecule called β5
integrin. My work focuses on taking a closer look at the change in cell adhesion properties in
ovarian cancer because they are a critical aspect of metastasis. Currently, I am using different
functional assessments to determine the role of β5 integrin in cell adhesion and spheroid
formation. Understanding how ovarian cancer cells alter their cell adhesion to allow for
metastasis may reveal unique vulnerabilities that could improve treatment outcomes for ovarian
cancer patients.
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Chapter 1

1. Introduction
1.1.

Epithelial ovarian cancer

Epithelial ovarian cancer (EOC) is the most lethal gynecological malignancy in the developed
world[1]. Most women are diagnosed with advanced-stage disease with a 5-year survival rate of
less than 29%, since 80% of these cases present initially with metastasis[1], [2]. The delay in
diagnosis can be attributed to the wide range of non-specific symptoms like abdominal fullness,
vaginal bleeding and urinary symptoms thereby leading to a more advanced-stage before clinical
assessment[3]. Factors for increased risk include early age of menarche, and benign gynecological
conditions such as endometriosis, polycystic ovary and pelvic inflammatory disease, whereas oral
contraceptive use and tubal ligation can decrease risk for EOC[1]. The current treatment plan for
patients with EOC in which tumors have spread beyond the ovaries is maximal surgical
cytoreduction with adjuvant chemotherapy of combined carboplatin and paclitaxel[1]. However,
75% of patients will have disease reoccurrence, oftentimes acquiring chemotherapy resistance,
ultimately leading to a dire prognosis[1], [3].
EOC encompasses a heterogenous group of malignant tumors that differ in prognosis,
molecular pathology, and etiology. According to the World Health Organization (WHO), EOC can
be classified into seven histological subtypes: high-grade and low-grade serous, mucinous,
endometrioid, clear cell, Brenner, seromucinous and undifferentiated carcinomas[4]. These
histological subtypes can be organized into two major EOC groups where Type I consists of lower
grade, slow-proliferating carcinomas within serous, endometrioid, mucinous and clear cell
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histological subtypes that likely arise from benign ovarian lesions[4], [5] . Whereas Type II tumors
are typified as being more aggressive disease derived from secretory fallopian tube epithelium,
and present histologically as high-grade serous, mixed epithelial or undifferentiated
carcinomas[5], [6]. High-grade serous ovarian cancer (HGSOC) represents 75% of all cases and
is characterized by the near universal presence of TP53 tumor suppressor gene mutations,
commonly as observed as missense gain-of-function alterations, although deletions and nonsense
loss-of-function mutations have been identified, too[7], [8] . This genetic alteration arises within
an early tumor precursor cell of the distal fallopian tube, called serous tubal intraepithelial
carcinoma (STIC) lesion; protein-stabilizing TP53 missense mutations promote secretory
epithelial cell survival and cell-cell aggregation under anchorage independent growth
conditions[8]. HGSOC is associated with lower prevalent but recurrent somatic mutations in NF1,
BRCA1, BRCA2, RB1 and CDK12 totalling 5-8% of tumors[1], [8].
Furthermore, advanced EOC is characterized by ascites fluid accumulation within the
peritoneal cavity[5]. The impairment of lymphatic drainage and increased secretion of vascular
endothelial growth factor (VEGF) leads to enhanced vascular permeability[5]. The unique
microenvironment within malignant EOC ascites consists of a variety of non-tumor cell types,
such as fibroblasts, mesothelial cells, immune cells and endothelial cells, as well as acellular
components, such as soluble extracellular matrix (ECM), matrix-degrading enzymes, cytokines
and growth factors[9].

1.2.

Extracellular Matrix interactions in EOC
The ECM is an integral and dynamic non-cellular component within all tissues and functions

to support cells and maintain tissue homeostasis[9]–[11]. Normal ovarian ECM is composed of a
highly-ordered arrangement of collagen fibers and proteoglycans, such as decorin and versican, to
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provide structural integrity, and maintain interstitial pressure and hydration to tissue[9]–[11].
However, ECM stiffness is commonly increased in EOC tumors through the activation of stromal
fibroblasts and collagen remodeling into thick fibrils in random orientation, which can combine to
increase tumorigenesis, cancer invasion and migration[10]–[12]. For example, decorin loss and
upregulation of versican, fibronectin, tenascin-C, and tenascin-X are associated with poor
prognosis and overall survival in EOC[9], [12]. The binding of various ECM ligands to integrins,
which are glycoprotein receptors at the cell surface to promote adhesion, regulate complex
signaling events alone or in combination with growth factor receptors[13], [14].
The interactions between the tumor cells and ECM within the tumor microenvironment are
crucial since their dysregulation has been implicated in EOC progression[9], [13]. Therefore,
integrin-mediated interactions and function within the tumor micro-environment represents a
potential unique therapeutic strategy in EOC. In this review, we discuss the contributions of
integrin-mediated cell adhesion in the critical steps during intraperitoneal metastatic cascade of
EOC pathogenesis, including spheroid formation, epithelial-mesenchymal plasticity, and
mesothelial attachment of secondary tumors.

1.3.

Integrin signalling

The integrins comprise a superfamily of cell adhesion receptors that recognize ECM and cellsurface ligands[15]. There are 18 α-subunits and 8 β-subunits that assemble to create 24
functionally distinct transmembrane heterodimers. Integrins are grouped according to their ligandbinding specificity: collagen-binding integrins (α1β1, α2β1, α10β1, and α11β1), laminin-binding
integrins (α3β1, α6β1, α7β1, and α6β4), leukocyte-integrins (α4β1, α9β1, α4β7, αEβ7,αLβ2, αMβ2, αXβ2,
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and αDβ2) and arginine-glycine-aspartate (RGD)-recognizing integrins (α5β1, α8β1, αVβ1, αVβ3,
αVβ5, αVβ6, αVβ8, and αIIbβ3)[15] (Figure 1.1).
These receptor complexes have no enzymatic activity but instead activate bidirectional
signaling pathways[13], [15]. The affinity of integrin receptors for ECM components and other
ligands is tightly regulated by inside-out signaling[15]. Integrin receptors maintain α and β subunit
cytoplasmic tail association during their inactive stage, and cytoplasmic signals from associated
G-protein coupled receptors lead integrin β subunit phosphorylation within its cytoplasmic domain
for receptor activation[15], [16]. The integrin binding of cytoskeletal proteins such as talin,
vinculin and ERM (ezrin, radixin, and moesin) acts to regulate actin microfilaments of the
cytoskeleton[15], [16]. In contrast, outside-in signaling occurs through the clustering of integrin
receptors at the plasma membrane where ECM ligation transduces signals intracellularly[15], [17].
Natural extracellular ligands include several components of the ECM such as collagen, laminin,
fibronectin and vitronectin[13], [15]. Extracellular ligand binding induces conformational changes
in the integrin receptor to allow intracellular tails of the β subunit to engage with intracellular
signaling molecules including focal adhesion kinase (FAK), small GTPases Rho and Ras, and
adaptors, such as Cas/Crk and paxillin[17]. These activated integrin-ECM interactions lead to the
formation of dynamic adhesion structures as small extensions from the plasma membrane called
podosomes[15], [16], [18] . After ECM ligation, integrins acting alone or in complex with growth
factors present in the local microenvironment can regulate diverse tumor cell functions, such as
migration, invasion, adhesion and proliferation through the activation of various signaling
pathways[13], [15].
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Figure 1.1
Integrins are a superfamily of cell adhesion receptors that recognize ECM and cell-surface ligand. They consist of 18
α-subunits and 8 β-subunits that assemble to create 24 functionally distinct transmembrane heterodimers. (a) Integrins
are grouped according to their ligand-binding specificity: arginine-glycine-aspartate (RGD)-recognizing integrins,
laminin-binding integrins, collagen-binding integrins and leukocyte-integrins. (b) Integrins take part in bidirectional
signaling once the integrins move from a bent configuration to an active form. During inside-out signaling, G-protein
coupled receptors lead to integrin β subunit phosphorylation within the cytoplasmic domain for receptor activation.
The integrin binding of cytoskeletal proteins such as talin, vinculin and ERM (ezrin, radixin, and moesin) acts to
regulate actin microfilaments of the cytoskeleton. Outside-in signaling occurs through the clustering of integrin
receptors at the plasma membrane where ECM ligation transduces signals intracellularly. ECM binding with ligands
such as collagen, laminin and fibronectin induces conformational changes in the integrin receptor to allow intracellular
tails of the β subunit to engage with intracellular signaling molecules including focal adhesion kinase (FAK), small
GTPases Rho and Ras, and adaptors, such as Cas/Crk and paxillin. Integrin acting alone or in complex with growth
factors present in the local microenvironment can regulate diverse tumor cell functions, such as migration, invasion,
adhesion and proliferation through the activation of various signaling pathways. [created via biorender.com]
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1.4.

Implications of integrin function in EOC metastasis

The primary site of origin for HGSOC is the secretory epithelial cells of the distal fallopian tube
from precursor STIC lesions[7], [19]. After TP53 mutations occur, it is postulated that cells within
precursor lesions can be further stimulated by local inflammatory cytokines, growth factors and
hormones, such as transforming growth factor-beta (TGF-β) and activin A present in follicular
fluid that can stimulate migration of STIC cells to the ovary[20]–[22]. The movement of STIC
lesions to the rich microenvironment provided by the ovary is a critical step in the transition of
STIC lesions to HGSOC by attaching, invading and establishing a primary tumor[1], [23]–[25].
This model has been supported by studies in which ovariectomies performed in mice harboring
precursor lesions results in reduced tumor formation and intraperitoneal metastasis, emphasizing
the importance of the ovarian microenvironment for complete malignant progression[23], [26].
Unlike hematogenous routes involving intravasation and extravasation where cancer cells
must penetrate multiple barriers, intraperitoneal dissemination is a common form of EOC
metastasis, and is also observed less frequently in colorectal, gastric and pancreatic cancers[5],
[27], [28]. Despite the more passive nature of intraperitoneal dissemination, it leads to rapid
disease progression, frequent relapse, complications like bowel obstruction, and overall poor
prognosis[5], [6]. During advanced-stage EOC, metastatic cancer cells impair lymphatic drainage
and secrete vascular endothelial growth factor (VEGF) that enhances vascular permeability and
ascites fluid accumulation in the peritoneal cavity[5], [29]. Ascites fluid often contains EOC cells,
as well as a highly heterogeneous mix of other cellular and acellular components[5], [9]. Direct
spread of EOC tumor cells into the peritoneal cavity is due to enhanced anchorage-independent
tumor cell survival that may be supported by altered cell-cell and cell-ECM functions of various
integrins.
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1.4.1. Integrins in EOC spheroids
EOC cells that are bound for metastatic dissemination must first detach from the primary tumor
site. Proteolytic activity by membrane type 1 matrix metalloproteinase (MT1-MMP, or MMP14)
is required in part for the initial detachment of EOC cells from the primary ovarian tumor by
cleaving α3 integrin on cancer cells and contributing to decreased cell adhesion[30]. Detached EOC
cells survive in hypoxic and anchorage-independent conditions by forming heterogenous
multicellular structures known as spheroids thereby avoiding anoikis, which is a specific form of
apoptosis triggered by the lack of attachment to other cells or ECM[5], [31], [32]. Spheroids further
complicate the disease by exhibiting decreased cell proliferation by accumulating in the G0/G1
phase of the cell cycle and becoming resistant to chemotherapeutic agents, such as paclitaxel and
cisplatin[33], [34]. It is important to appreciate, however, that not all cells within spheroids may
have the same properties. For example, spheroids can move in a coordinated fashion, a process
called collective migration. This is driven by outer “leader” cells that direct migration and enable
the invasion of basement membrane, then “follower cells” that mediate actomyosin contraction
allowing for cellular movement[35], [36].
The first step of spheroid formation consists of cell-cell interactions either directly or through
ECM bridges. The abundance of integrins available to cells within these multicellular aggregates
may provide a major contribution to spheroid formation and pro-survival signaling[37]. Doberstein
et al. demonstrated that the loss of L1 cell adhesion molecule (L1CAM) reduced the capacity for
OVCAR8 cells to form spheroids, ultimately leading to cell death[26]. Alternatively, L1CAM
overexpression led to increased spheroid formation in OVCAR8 cells as well as multiple
immortalized human fallopian tube epithelial cell lines[26]. L1CAM expression promotes the
upregulation of fibronectin and integrin subunits α5 and β1, which together promote cell
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aggregation into spheroids yet detachment from the primary tumor and tumorigenesis[26].
Fibronectin is abundant within the ascites and plays a critical role in spheroid integrity[38], [39]
by interacting with its canonical integrin receptor α5β1[40], [41]. For example, OVCAR5 spheroids
co-express of α5β1 integrin and fibronectin on the their surface[41]. The functional inhibition of β1
integrin using an inhibitory antibody results in the disruption of EOC spheroids, whereas β1
integrin clustering and fibronectin activate α5β1 heterodimer assembly to promote spheroid
formation[41].
Spheroid compaction into dense aggregates is critical for tumorigenesis and related to their
actomyosin contractile capacity mediated by integrins and cadherins[39], [42]. A positive
correlation may exist between compact spheroid formation and tumorigenic capacity, as well as
enhanced invasive capacity in EOC[42]. Sodek et al. demonstrated that β1 integrin activation using
an activating antibody 12G10 and ectopic β1 integrin upregulation enhanced more compact cell
aggregation using SKOV3 and OVCAR3 cells, two EOC cell lines that typically form less compact
spheroids[42]. Conversely, treating compact HEY cells spheroids with a β1-integrin blocking
antibody MAB13 led to spheroid disaggregation[42]. Casey and colleagues also demonstrated that
treating OVCAR5 cells with a β1-integrin blocking antibody inhibits spheroid formation, while
addition of exogenous fibronectin promoted EOC spheroid formation[41]. Similarly, laminin
interactions with α6β1 integrins, and collagen with α2β1-integrins, mediate spheroid formation[41],
[43]. In contrast, spheroid formation can be enhanced in the presence of antibodies targeting α2,
α4, α6 or αvβ3 integrins implicating these integrins may negatively regulate spheroid formation[41].
Kellouche and colleagues identified αv integrin and vitronectin colocalization within
multicellular aggregates at intercellular sites suggesting a contribution in cell-cell interactions[44].
They demonstrated through the use of anti-vitronectin, anti-αv integrin, or the cyclic peptide
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cRGDfV, blocked initial formation of IGROV1 spheroids[44]. The blockade of αv integrins
decreased integrin-linked kinase (ILK) activity resulting in reduced Akt phosphorylation and
increased cell cycle inhibitor p27kip1 expression[45]. αv integrin can directly regulate ILK activity
since anti-αv integrin inhibits ILK activity whereas ectopic ILK overexpression rescues the
inhibitory effect of αv integrin blockade[45]. Anchorage-independent growth of IGROV1 cells
leads to a significant decrease in ERK1/2 phosphorylation compared to adherent cells and
inhibition of ERK1/2 activation with MEK1/2 inhibitor U0126 in IGROV1 spheroids led to a
decrease in the number of viable cells and increase in PARP cleavage and caspase-3 activity[46].
Carduner et al. show that increased anoikis in IGROV1 spheroids due to αv-integrin silencing is
associated with decreased ERK1/2 activation. This suggests that αv-integrin promotes spheroid
cell survival by inducing ERK-dependent pathways[46]. This association has also been
demonstrated in an anoikis-resistant population of human intestinal carcinoma cells due to αvβ3
integrin expression[47].
Cancer stem-like cells (CSC) may play a role in EOC spheroid formation. Exogenous CD90
decreased SKOV3 spheroid formation and promoted apoptosis as seen by increased cleaved poly
(ADP-ribose) polymerase expression[48]. Ectopic CD90 expression led to decreased expression
of CSC markers CD133 and CD24, and promoted mTOR phosphorylation as well as its
downstream target AMPK[48]. However, β3-integrin silencing increased anchorage-independent
growth and CD133 marker expression. CD90 is associated with αvβ3 integrin through its regulation
of signal transduction in astrocytes and neuronal cells[49]. Taken together, this suggests negative
regulatory role of CD90 together with β3-integrin signaling in the context of CSCs and the EOC
spheroid phenotype.
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Spheroids present in malignant ascites can interact with other cell types to affect their
phenotype. For example, an analysis of cell components in spheroids isolated from the ascites of
128 patients with stage III ovarian cancer showed the presence of macrophages in all
spheroids[50]. The number of macrophages present with spheroids compared to primary tumors
was substantially higher and positively correlated with proliferation in spheroids and negatively
with patient prognosis[50]. Robinson-Smith et al. demonstrated spheroid implantation in a mouse
model of EOC increased due to inflammation, whereas the loss of peritoneal macrophages reduced
metastatic potential, supporting the role of tumor-associated macrophages (TAMs) in EOC[51]. In
fact, Yin et al. discovered that EOC spheroids express ICAM1, a ligand that binds leukocyteassociated integrin subunits αM and αX. Blockade of this interaction between EOC cells and TAMs
diminished spheroid formation in mouse and human in vitro spheroid coculture models[50] TAMs
are a source of epidermal growth factor (EGF), and EGF signaling is critical for EOC cell
proliferation to increase VEGF-C and enhance integrin-ICAM1 expression, spheroid formation
and migration[50].

1.4.2. Integrins in epithelial-mesenchymal transition and EOC cell migration
Cancer cells destined for dissemination co-express epithelial and mesenchymal markers,
commonly referred to as epithelial-mesenchymal transition (EMT), allowing for a cadherin
switch[36], [52]. EMT allows ovarian cancer cells to loosen intercellular adhesions between cells
contributing to the transition of cells from a primary tumor to shed as single cells or spheroids into
the ascites[5], [39]. During this EMT process, cancer cells gain a more invasive properties, survive
in hypoxic conditions, and spread through the abdominal cavity by the peritoneal fluid flow[53].
The decrease in cell-cell adhesion and detachment of EOC cells from the primary tumor into the

10

peritoneal cavity is mediated through the integrin-mediated upregulation of matrix
metalloproteinases (MMPs) and activation of EMT[36]. Clustering of collagen-binding integrins
α2β1and α3β1on EOC cells leads to the induction of MMP9, which is capable of E-cadherin
ectodomain cleavage and cell-cell adhesion loosening in an Src kinase-dependent manner[54]. Ecadherin loss leads to transcriptional upregulation of fibronectin receptor α5β1 integrin, which is
essential when spheroids initiate adhesion at a secondary site[55]. Decreased E-cadherin is also
accompanied by reductions in occludins, claudins, epithelial cell adhesion molecule (EpCAM),
α6β4 integrin and cytokines, all of which act to stabilize tight cell-cell contacts via
desmosomes[22]. In a reciprocal fashion, there are increases in vimentin, fibronectin, N-cadherin,
β1 and β3 integrins and matrix metalloproteinases[22]. Forced downregulation of E-cadherin in
EOC cells increases α5 integrin expression through focal adhesion kinase (FAK) and ERK1
activities leading to enhanced cell adhesion to fibronectin[56]. As expected, these EMT-like
changes due to E-cadherin loss promote EOC cell invasive properties required for metastasis[53].
TGF- signaling is widely-recognized as one of the most important pathways required to
promote EMT in human cancers. We have demonstrated that TGF-β activity is induced during
ascites-derived EOC spheroid formation as indicated by increased mesenchymal marker
transcripts, whereas TGF-β signalling inhibition dramatically reduces EMT properties and cellcell cohesion within spheroids[57]. Bianchi et al. have shown that β integrin subunits associated
with αv integrin are upregulated during TGF-β induced EMT in breast carcinoma, and specific
integrin β5 downregulation blocked TGF-β induced EMT[58]. Similarly, αvβ8 integrin mediates
latent TGF-β activation and resultant EMT in various cancers contributing to cell migration and
growth[59].

11

The ascites microenvironment may play a critical role in promoting a partial shift towards a
mesenchymal phenotype in EOC cells[46]. When cultured EOC cells are exposed to ascites, αv
integrin localization moves from focal contact structures to intracellular perinuclear vesicles in
IGROV1 cells[46]. In a pulse-chase experiment, Carduner et al. showed IGROV1 cells exposed
to ascites led to centripetal movement of αv integrin, whereas they remain localized to focal
contacts in standard culture medium[46]. Furthermore, the αv integrin cyclic antagonist cRGDfc
peptide inhibited multicellular aggregate formation by 40% compared to a non-targeting control
peptide[46]. Although these studies suggest that αv-integrin and TGF-β work in concert to control
EMT, cell adhesion and migration, a broader role of αv integrin complexes in EOC pathogenesis
remains unclear and further investigation is required.
When establishing secondary tumors, spheroids attach to the mesothelium lining through the
interactions between spheroids and surface receptors on the mesothelial layer[22], [60]. At this
point, spheroid cells induce expression of several integrins that prime the spheroids for attachment
to the mesothelium and underlying ECM proteins[22], [41], [61]. For example, interaction between
spheroid cells expressing α5β1 integrin receptor and the mesothelium containing fibronectin matrix
is essential for spheroid adhesion[41]. Although Cannistra et al. showed that neutralizing
antibodies against α5β1 and αvβ3 integrins did not affect the binding of EOC cells to the
mesothelium, additional studies by this group and others have shown a partial block in adhesion
when inhibitory β1 integrin antibody was administered[41], [62], [63]. Similarly, inhibition of α3,
α6 and β1 integrin subunits decrease invasiveness and collagen-binding of spheroids[36]. As the
major receptors for ECM proteins, integrins pose as critical regulators of cancer cell adhesion and
invasion at a secondary site.
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1.4.3. Integrin-mediated mesothelial attachment and migration
The final step of EOC metastasis occurs when spheroids alter adhesion between tumor cells,
penetrate mesothelial surfaces, and degrade the ECM within the basement membrane underlying
the peritoneum, omentum and abdominal organs[64]. An early step in this process is the integrinmediated binding of EOC cells to mesothelial cells and exposed ECM[65]. Kaur et al.
demonstrated that β3 integrin expression correlates with increased EOC cell adhesion in vitro and
adhesion to mesothelium and mouse omentum in vivo[65]. However, they also showed that αvβ3
overexpressing cells inhibited cell Matrigel invasion, and β3 integrin blockade resulted in enhanced
invasion in CAOV3 and MONTY1 cells[65]. These latter results were recapitulated in vivo where
αvβ3 overexpressing cells displayed a 35% decrease in intra-abdominal metastases and 53%
decrease in tumor weight compared to controls[65]. These results highlight the potential
mechanistic differences involving integrins between EOC cell adhesion, invasion, and successful
secondary tumor formation.
Integrins function in both cell-cell adhesion and binding to basement membrane and ligand
components[64]. α2 and β1 integrin subunits contribute to EOC cell adhesion via collagen I
facilitating peritoneal attachment and invasion into the mesothelial monolayers[66]. Studies have
consistently shown that inhibition of collagen-associated integrins α2β1 lead to attenuated spheroid
disaggregation on artificial ECM since primary EOC cells adhere preferentially to type I
collagens[54], [62], [67]. Furthermore, Davidson et al. showed high expression of αv and β1 integrin
subunits in malignant cells from peritoneal and pleural effusions collected from late-stage EOC
patients suggesting a potential role in metastasis[68]. The interaction between vascular cell
adhesion molecule 1 (VCAM-1) present on the mesothelium and α4β1 integrins on EOC cells
promotes metastasis and cell migration in xenograft models[69]. Indeed, this study also
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demonstrated that the use of function-blocking antibodies against either VCAM-1 or α4β1 integrins
show promise in decreasing EOC metastasis[69].
Recent studies suggest that EOC cells may not adhere directly to mesothelial cells, but rather
to underlying connective tissue; this is achieved by disrupting cell-cell junctions, a process called
mesothelial cell clearance[70]. Iwanicki et al. demonstrated that EOC spheroids use integrin- and
talin-dependent activation of myosin traction force to promote mesothelial cell clearance[70]. In
this experimental model, mesothelial cell monolayers were plated on fibronectin-coated
polyacrylamide gels to mimic physiologically-relevant stiffness of connective tissue. They showed
that OVCA433 spheroids induced mesothelial clearance by the above mechanisms[70]. As
spheroids promote mesothelial clearance, fibronectin fibrils organized on top of mesothelial cells
are redistributed away from between the mesothelium and attaching spheroids[70]. Blocking of α5
integrin, talin 1 and non-muscle myosin II abrogated mesothelial displacement, while ectopic
expression of α5 integrin increased myosin-mediated cell spreading, stress fibers, and other cortical
actin contractile structures[70]. Collagen I-associated α2 integrin subunit induced fibril
reorganization and transmitted traction forces to ECM, but spheroids expressing high levels of α2
integrin rather than α5 integrin were unable to clear the mesothelium[70]. Interestingly, blockade
of another fibronectin receptor αvβ3 integrins did not affect mesothelial clearance, suggesting these
specific receptors do not have a myosin-contractility roles in EOC metastasis[70]. In a different
study, Kokenyesi et al. reported SKOV3 and OVCAR3 cells were unable to invade a collagen I
matrix due to their inability to disrupt intracellular interactions, highlighting the importance of
integrin-mediated actomyosin contraction to overcome cell-cell attachments[71].
A critical component of tumor invasion is enzymatic degradation of the ECM, which permits
cancer cells to penetrate the basement membrane, gain access to the vasculature and successful
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formation of secondary tumor growth[40]. Spheroid cell migration using OVCAR5 cells on
laminin and collagen IV-coated surfaces showed a modest 2-fold change in cell migration over 24
hours, whereas spheroids on fibronectin and collagen I completely disaggregated to form a
monolayer with a 9-fold change in surface area[40], [61]. Addition of an inhibitory antibody
against β1 integrin completely eliminated spheroid cell migration on laminin, fibronectin and typeIV collagen, and a 50% reduction on type-I collagen[40], [61]. However, these results suggest that
β1 integrin blockade did not prevent initial spheroid attachment, but rather significantly impacted
ECM degradation and spheroid disaggregation of invading foci[40]. Overall, β1 integrins partially
mediate adhesion of EOC spheroid cells to ECM, but likely plays a more significant role in its
degradation and resultant spheroid disaggregation[40], [61].
MMPs are zinc-dependent proteinases that degrade various ECM components, such as
collagens, proteoglycans, gelatins, vitronectin, and fibronectin[72]. EOC cells that express higher
levels of MMP2 and MMP9 possess increased invasive and metastatic potential[67], [73]. Studies
by Kenny et al. demonstrated that contact of EOC cells with mesothelium induces MMP2
expression at the transcriptional and translational levels[74]. Activated MMP2 cleaves various
ECM components, including vitronectin and fibronectin, into smaller fragments to improve EOC
cell adhesion to αvβ3 and α5β1integrin receptors[74]. αvβ3 and α5β1 blocking antibodies inhibited
cell adhesion, however, this effect was abolished when EOC cells were preincubated with MMP2
antibody[74].
When cells migrate away from the core of an attached spheroid, cell-cell contacts are reduced
while adhesion and spreading on ECM occurs[67]. Compared to monolayer culture, MMP2 and
MMP9 activities are increased in serum-free medium collected from spheroid culture[67].
Increased α2 integrin and decreased α6 integrin subunits in OVHS1 and HEY spheroids were also
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observed[67]. Interestingly, Shield et al. demonstrated OVHS1 and HEY spheroids have reduced
disaggregation in the presence of α2, β1 and α2β1 integrin with a coordinated reduction in active
MMP2 levels[67].
Furthermore, expression of αvβ6 in EOC is correlated with increased expression and secretion
of high molecular weight-urokinase-type plasminogen activator (uPA), pro-MMP2 and proMMP9, in tumor-conditioned media[73]. Interestingly, αvβ6 integrin expression is restricted to
metastatic EOC cells with little to no expression in benign and normal ovarian epithelial cells[75].
Ahmed et al. suggest that αvβ6 integrin-expressing EOC cell lines have an enhanced capacity to
degrade the basement membrane in a plasminogen-dependent manner since this effect was
completely abolished by inhibition of uPA, MMP9, and αvβ6 integrins[73].

1.5.

Integrins as therapeutic targets for EOC
Novel therapies that focus on malignant cells and the tumor microenvironment in EOC have

gained substantial interest due to the heterogeneity of the disease. As described in detail above,
integrins are key regulators at various steps in the unique metastatic cascade of this disease,
particularly in spheroid formation, and for peritoneal invasion where integrin-ECM interactions
are essential for initiating spheroid adhesion[36]. Insight into the cellular mechanisms involved in
cancer cell survival and progression over the last decade have led to the development of integrin
inhibitors[13]. Preclinical and clinical studies of integrin antagonists show promising results in
effectively blocking tumor progression[76].
Integrin inhibitors represent a feasible therapeutic strategy since the majority of Phase I
clinical trials demonstrate that these agents are well-tolerated by patients in conjunction with
cytotoxic chemotherapy or radiotherapy[13], [36]. The chimeric monoclonal antibody
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Volociximab targets α5β1 integrin and has been successful in inhibiting angiogenesis and
impairment of tumor growth[77]. Preclinical data shows that intraperitoneal treatment of
SKOV3ip1 xenografted mice with Volociximab reduced tumor burden and ascites accumulation
by 83% and 97%, respectively[77]. Encouragingly, clinical trials showed that EOC patients with
platinum-resistant disease treated with a weekly administration of Volociximab was well
tolerated[78]. ATN-161 is a non-RGD based synthetic pentapeptide derived from fibronectin that
binds to and blocks both α5β1 and αvβ3 integrins[79]. This agent has shown promise using mouse
xenograft models of breast cancer metastasis and it was safe in patients with stable disease in Phase
I trials, but has not been tested in EOC patients yet[80], [81]. Etaracizumab is an anti-human
monoclonal antibody against αvβ3 developed after encouraging preclinical results showing
decreased tumor burden in SKOV3ip1 and HEYA8 xenograft mouse models[82]. However,
clinical trials showed minimal effectiveness as a therapeutic treatment for metastatic disease[79].
Another humanized antibody Intetumumab targeting αvβ3 and αvβ5 showed effective inhibition of
cancer cell adhesion and migration of six different uterine serous papillary carcinoma cell lines in
vitro[83]. Phase I clinical trials show that it is safe, it localized to tumors, and shows signs of
potential anti-tumor activity, but these early findings require additional trials[84]. Although
promising results have been seen with anti-integrin αvβ3 antibodies, results from Kaur et al. suggest
that of αvβ3 overexpression in fact correlates with favorable patient outcome; thus, further clinical
investigations are required[65].
Although approaches for targeting integrins may offer therapeutic potential in the future, no
single integrin receptor complex inhibition strategy has shown sufficient clinical trials results to
progress for further investigation yet[36]. One major hurdle impeding success may be the
complexity and dynamics of integrin functions implicated in EOC tumor growth and metastasis
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(Figure 1.2). For instance, the crucial interaction of EOC cells for adhesion via fibronectin is not
limited to α5β1 integrin, as αvβ3 or α3β1 integrins can compensate for loss of function[36]. Adding
to this challenge will be the broad intratumor and interpatient heterogeneity in this disease. Taken
together, we foresee that a combined approach of targeting multiple integrin-associated pathways
may be worthy of future exploration in both experimental and clinical applications.
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Figure 1.2
A schematic model of ovarian cancer dissemination and the role of integrins in cancer metastasis. The primary site of
origin for HGSOC is the secretory epithelial cells of the distal fallopian tube from precursor STIC lesions and the
increase in L1CAM and increased ligation of fibronectin to α5β1 promotes cell detachment. Detached EOC cells
survive in hypoxic and anchorage-independent conditions by forming heterogenous multicellular structures known as
spheroids to avoid anoikis. Spheroid formation can be enhanced with the interaction of integrins with various ECM
proteins. Integrins such as α2β1 and α3β1 clustering leads to the loosening of intercellular adhesions between cells and
contributes to EMT-MET switching. The final step of EOC metastasis occurs when spheroids penetrate mesothelial
surfaces, and integrin-mediated degradation of the ECM within the basement membrane underlying the peritoneum
leads to secondary metastasis. [created by biorender.com]
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1.6.

The role of β5 Integrin in cancer pathogenesis
Integrin β5 (ITGβ5) encodes for an integrin subunit that interacts with the integrin αv to

form a functional transmembrane heterodimer[13]. It is present on the surface of several cancer
subtypes and interacts with ligands with the arginine-glycine-aspartate (RGD) sequence
motif[13, 92]. Although no selective ligand has been identified for integrin 𝛽5 , it is less
promiscuous than other integrins and binds preferentially to vitronectin and most small
molecules that bind to the heterodimer αvβ3 [93, 94]. Previous studies have shown that integrin
β5 is a prognostic bio-marker within various malignancies including human pancreatic, breast,
gastric and ovarian cancers [95–98]. Although, a new study aimed to explore the prognostic
values of the integrin superfamily in HGSOC using The Cancer Genome Atlas (TCGA) and
GSE9891dataset found that Integrin β5 was significantly downregulated in HGSOC compared to
control groups [92].
There has been accumulating evidence of β5 integrin facilitating cell survival,
angiogenesis, cancer cell migration, invasion and transforming growth factor β (TGF- β) induced
EMT [58, 100, 101]. Hood et al. show that αvβ5 and αvβ3 contribute to sustained Ras-extracellular
signal-related kinase (Ras-ERK) signaling in blood vessels, which is a requirement for
endothelial cell survival and angiogenesis [93]. In Glioblastoma, integrin β5 overexpression is
not only associated with poor patient survival but also promotes migration and invasion in
glioma cells [94]. Furthermore, there is evidence that integrin β5 plays a role in carcinoma cell
motility through the binding of PAK4, a p21-activated group II kinase, to the cytoplasmic
domain of integrin β5 [95]. The group show that the engagement of integrin β5 and vitronectin
led to the redistribution of PAK4 from cytosol to colocalization with integrin β5 and ultimately
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human breast carcinoma cell migration [95]. The depletion of integrin β5 in triple-negative breast
carcinoma cells reduces the tumor take, growth and angiogenesis, whereas the re-expression of
integrin β5 can rescue this phenotype [89]. Bianchi et al. revealed that integrin β5 mediates SrcFAK and MEK-ERK signaling events and inhibition of these pathways produces the same
phenotype as integrin β5 deficiency [89]. Interestingly, integrin β5 is associated with enhanced
cell glycolysis to promote cancer cell growth and proliferation and counteracting cisplatin
cytotoxicity in breast and cervical cancer cells [96]. Wang et al. demonstrated that Src-induced
phosphorylation of FAK at Tyr861 was involved in integrin β5-mediated glycolysis, further
expanding the different functions of integrin β5—FAK signaling [96].
TGF-β signaling is critical for various functions such as apoptosis, cell proliferation,
differentiation, adhesion, tumor progression and the promotion of EMT [104–107]. Using
mRNA sequencing data and clinical prognostic information of hepatocellular cancer patients
from TCGA database, integrin β5 was identified as EMT associated gene and part of a 5-gene
prognostic risk model for patients [101]. In colorectal cancer, Shi et al. show that higher integrin
β5 expression is associated with EMT process and TGF- β signal activation [102]. When integrin
β5 was silenced, the EMT process was attenuated because there was reduced Smad
phosphorylation by the decrease in Snail1, Twist1 and TGFβ1 [102]. These results suggest that
the upregulation of integrin β5 may possibly enhance TGF-β signaling and the EMT process,
thereby promoting tumor growth and metastasis in colorectal cancer [102]. These findings are
consistent with previous reports that show the loss of integrin β5hinders breast carcinoma cell
growth, tumor angiogenesis and migration by inhibiting Src/FAK and MEK/ERK signaling [89].
Bianchi et al. highlights the upregulation of integrin β5 during TGF-β induced EMT in breast
carcinoma that requires the Smad transcription factors [58]. The depletion of integrin β5
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significantly reduced the invasiveness of breast carcinoma cells, blocked the TGF-β induced
EMT and therefore impairing adhesion to cell-matrix and integrin signaling [58]. Although it has
been shown that intact TGF-β signaling is critical to control EMT in EOC ascites-derived
spheroids and promotes the malignant characteristics of these structures, the relationship between
TGF-β and integrin β5 in ovarian cancer in unclear [57].
While there is a body of literature that suggests roles of integrin β5 in various
malignancies, the function of integrin β5 within ovarian cancer is limited. Gillan et al. suggest
that Periostin (PN), formerly called osteoblast-specific factor-2, is secreted by EOC cells,
accumulates in the ascites and functions as a ligand for integrins αvβ3 and αvβ5 to promote EOC
dissemination, cell adhesion and migration [103]. They show that purified recombinant PN
supports EOC cell adhesion that can be inhibited by a monoclonal antibody against αvβ5 and αvβ3
but not anti-β1 [103]. Moreover, Maubant et al. derived a cisplatin-resistant cell line, IGROVR10, and when grown in monolayer culture, they have an enhanced ability to spontaneously
release cell clusters with high proliferative abilities [104]. Compared to the parental IGROV1
cells, IGROV-R10 cells show a strong enrichment of αvβ5 on the surface of monolayer cells as
well as the spontaneously formed cell clusters in suspension [104]. This highlights the
chemoresistance associated dysregulation of integrin expression on cell surfaces and is the first
report to access the altered expression of integrin β5 due to cisplatin resistance [104].
Furthermore, integrin β subunit activate a common set of cytoplasmic tyrosine kinases such as
FAK, a gene that is amplified by 24% in serous ovarian cancer and is associated with decreased
overall patient survival [76, 112]. Tancioni et al. show that the inhibition of FAK or integrin β5
knockdown reduce ovarian tumor cell growth under anchorage-independent conditions, which
corresponds to decreased orthotopic tumor growth [91]. It seems that FAK inhibition disrupts the
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autocrine or paracrine signaling that regulates integrin β5 in addition to osteopontin levels in
ovarian carcinoma cells [91].

1.7.

Role of LKB1-NUAK1 signaling in EOC Tumor Progression
The revelation of important molecular pathways in spheroid formation would increase

understanding of metastasis and potentially uncover novel therapeutic targets. Liver Kinase B1
(LKB1) is encoded by the STK11 gene and is a serine-threonine master kinase[106]. It is widely
expressed in established ovarian cancer cell lines and patient derived ascites[107]. LKB1
expression increases in ovarian cancer spheroids compare to monolayer, suggesting an important
role in spheroid formation [107]. Our group has shown that LKB1 is critical for metastasis and
the loss of LKB1 can decrease anchorage-independent growth and viability of spheroids[108].
LKB1 is activated when it forms a complex with accessory proteins STRAD and MO25 [109].
LKB1 can then activate downstream target AMP-activated protein kinase (AMPK), which
regulates metabolic stress through phosphorylation modification of threonine 172 [109]. This
results in the coordinated downregulation of anabolic pathways and upregulation of catabolic
pathways in order to create homeostasis [109]. Our group went on to show that LKB1 ablation
resulted in significantly decrease number of viable cells and increased dead cell count in
spheroids culture of EOC cell lines tested [108]. This highlights the tumor forming and
metastatic potential of EOC cells by the loss of LKB1. However, our group has shown that
LKB1 pro-metastasis role in ovarian cancer occurs through AMPK-independent signaling
because in spheroids lacking LKB1, p-AMPK levels were maintained [108]. This suggests that
the ability of LKB1 to regulate 12 other AMPK related kinases may represent other targets by
which LKB1 maintains spheroid formation and cell viability.
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One of the top substrate identified by multiplex inhibitor beads-mass spectrometry
analysis from the loss of LKB1 is NUAK1 [38]. NUAK1 can function in tumor progression
through regulating apoptosis, invasion and metastasis in tumors [110]. For instance, loss of
NUAK1 led to a reduction of ATP levels and decreased proliferation in hepatocellular and
pancreatic carcinoma cells [111]. In ovarian cancer specifically, NUAK1 overexpression has
been linked to lower progression free survival and lower overall survival [112]. Furthermore,
there is an increased risk of advanced stage diagnosis and reoccurrence after cytoreduction
surgery [112]. NUAK1 has increased expression in spheroids compared to monolayer and is
involved in increasing EOC cell adhesion [38]. By examining NUAK1 Knock out (KO) green
fluorescent protein (GFP) labeled spheroids, we were able to evaluate spheroid formation. It was
observed that the loss of NUAK1 creates spheroids that are less compact and with an
accumulation of dead cells around the periphery [38]. NUAK1 appears to impair single cell
adhesion and spheroid formation. We postulate that NUAK1 regulates cell adhesion and ECM
interactions to help form spheroids that spread through the peritoneal cavity. Through Gene Set
Enrichment analysis (GSEA), the hallmark database revealed multiple cell attachment pathways
involved in integrin cell attachment that were differentially expressed in NUAK1 knockout
spheroids [38]. The FN1 gene encoding fibronectin, a known critical ECM protein in EOC
spheroids, showed a 745-fold decrease in the NUAK1 knockout spheroids [38]. When comparing
OVCAR8 parental monolayer cells to spheroids, there was an increase in fibronectin expression
with the presence of multiple isoforms [38]. However, in OVCAR8-NUAK1KO spheroids, there
was no detectable expression of fibronectin, suggesting NUAK1 may be critically required for
the expression of fibronectin. Interestingly, when soluble fibronectin was reintroduced
to NUAK1KO spheroids, native spheroid formation was rescued [38]. Altogether, this revealed a
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new mechanism through which NUAK1 promotes EOC cell adhesion and spheroid compaction
through fibronectin matrix production.

1.8.

Research goal, hypothesis and objectives
Our previous studies show that the ablation of LKB1-NUAK1 signaling pathway in EOC

cells resulted in a substantial loss of fibronectin expression leading to spheroid disaggregation
[38]. Numerous studies have shown that fibronectin binds to its canonical receptor α5 β1 in
ovarian cancer but there was no differential expression of this receptor [6], [41]. Our
transcriptome analysis demonstrated a coordinated reduction in β5 integrin expression due to
NUAK1 loss [38] and therefore, I sought to investigate the function of β5 integrin in ovarian
cancer. I hypothesize that of β5 integrin is required for epithelial ovarian cancer cell adhesion,
spheroid formation and subsequent spheroid reattachment. To test this hypothesis, I
characterized the mRNA expression of β5 integrin using publicly-available databases and protein
expression using western blot analysis of established and patient ascites-derived EOC cell lines.
Furthermore, I performed siRNA-mediated knockdown in established cell lines in monolayer and
anchorage independent culture to assess the functional role of β5integrin using cell adhesion, cell
viability, spheroid viability and reattachment assays. This project has allowed me to elucidate the
role of β5integrin in ovarian cancer cell adhesion and spheroid reattachment which have not
previously been explored.
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Chapter 2

2. Materials and Methods
2.1.

Expression Analysis using Publicly Available Datasets

To obtain the expression level of ITGB5 and ITGB8 we downloaded RNAseq TPM gene
expression data for protein coding genes RSEM from Depmap (Source: DepMap, Broad (2021):
DepMap 21Q2 Public. figshare. Dataset. (https://doi.org/10.6084/m9.figshare.14541774.v2).
Counts are Log2 transformed, using a pseudo-count of 1. Prior to downstream analysis dataset
was filtered by removing all samples that were not identified as 'Ovarian Cancer' in 'disease'
column. RNAseq data was downloaded from cBioportal using all integrin gene names as query
search. The provisional ovarian serous carcinoma dataset for solid tumour data (n=606) was used
and the 47 ovarian cancer cell lines from the Cancer Cell Line Encyclopedia data was used.

2.2.

Cell culture and treatments

OVCAR3, OVCAR5, OVCAR8, CAOV3, HEYA8, COV362, OVCA 420 and OVCA 433 cells
were cultured in RPMI-1640 (Wisent, St. Bruno, QC). FT190, TOV21G, ES-2, 105C, KOC7C,
OVTOKO, OVMANA, SMOV2, and the patient ascites-derived (iOvCa) cells were cultured in
DMEM-F12 (Life Technologies). For all cell lines growth medium was supplemented with 10%
FBS (Wisent, St. Bruno, QC). OVCAR3, OVCAR5, OVCAR8, CAOV3, HEYA8 cells were
obtained from ATCC. COV362 cells were received from Z. Khan (University of Western
Ontario, London, ON). The immortalized human fallopian tube secretory epithelial cell line
FT190 was provided by R Drapkin (University of Pennsylvania, Philadelphia, PA). The iOvCa
cell lines were established by Dr. Gabriel DiMattia (University of Western Ontario, London,
ON) based on a protocol described previously [113]. TOV21G was provided by Dr. Anne-Marie
Mes-Masson (University of Montréal, Montreal, QC) and ES-2, OVCA 420 and OVCA 433 are
from Dr. Barbara Vanderhyden (University of Ottawa, Ottawa, ON). The 105C originally
referred to as SCHM-1 were obtained from Dr. Hal Hirte (McMaster University, Hamilton, ON).
KOC7C, OVTOKO, OVMANA and SMOV2 were kindly provided by Dr. Hiroaki Itamochi
(Iwate Medical University, Iwate-ken, Japan).
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Cells were grown in a humidified incubator at 37°C with 5% CO2. Adherent cells were cultured
on tissue cultured-treated polystyrene (Sarstedt, Newton, NC). Spheroids were formed by
culturing cells on ultra-low attachment dishes (Corning, NY) that have a hydrophilic and neutral
coating to allow for cell clustering as described previously [33].

2.3.

Small-interfering RNA Transfection

Cells were seeded in 6-well dishes and seeding density per well was based on proliferation of
each cell line. FT190 cells were seeded at a density of 3.0 x 105 cells/well, OVCAR8 1.25 x 105
cells/well, HEYA8 1.5 x 105 cells/well, TOV21G 2.0 x 105 cells/well, and ES-2 1.0 x 105
cells/well. After 24 hours, cells were transfected according to the manufacturer’s protocol
(Dharmacon, Thermo Fisher Scientific). The combination of 4 μL DharmaFect-1 (T-2001-02)
with 10 nM of siRNA in 2 ml of media was incubated for 30 minutes. ITGβ5 (L-004125-000005) and non-targeting control pool (D-001206-14-05) siGENOME SMARTpool siRNAs were
obtained from Dharmacon. The combined siRNA/DharmaFect1 complexes were added to each
well containing cell and incubated at 37°C with 5% CO2. After 24 hours, the transfection media
was replaced and 72 hours post transfection, cells were trypsinized and seeded for adherent and
spheroid culture for experimental conditions. Lysates were also collected 3 days posttransfection for western blot analysis.

2.4.

Immunoblot analysis

Whole cell lysates from were obtained from 3 days of adherent culture or 3 days post
transfection. Cells were collected by washing the wells with PBS and scraping cells in lysis
buffer [50mM HEPES pH7.4, 150 mM NaCl, 10% glycerol, 1.5 mM MgCl2, 1 mM EGTA, 1
mM sodium orthovanadate, 10 mM sodium pyrophosphate, 10 mM NaF, 1% Triton X-100, 1%
sodium deoxycholate, 0.1% SDS, 1 mM PMSF. 1X protease inhibitor cocktail (Roche, Laval,
QC), and 225mM β-glycerophosphate]. Protein concentration was determined with Bradford
assay (Bio-Rad Laboratories, Hercules, CA).
Protein samples were prepared using 30 μg of protein determined by Bradford assay and
resolved by SDS-PAGE using 6% or 8% gels for ~ 2.5 hours. Electrophoresis was followed by a
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1 hour wet-transfer onto PVDF membrane (Immobilon-P) at 100 V. Membranes were blocked
for 1 hour with 5% Bovine Serum Albumin (BSA) diluted in TBST (10 mM Tris–HCl, pH 8.0,
150 mM NaCl and 0.1% Tween-20). Primary antibody against ITGβ5 (1:1000 dilution in 5%
BSA, Cell signaling #3629), Tubulin (1:20 000 dilution in 5% BSA, Sigma T5168) and Vinculin
(1:20 000 dilution in 5% BSA, Sigma V9264) was left on membranes overnight at 4°C. Next
day, membranes were washed 3x with TBST for a total for 45 minutes. Membranes were then
incubated for 1 hour with peroxidase-conjugated anti-rabbit (1:10 000 dilution in 5% BSA,
Sigma NA934V) or anti-mouse (1:10 000 dilution in 5% BSA, Sigma NA931V) antibodies and
washed 3x for 45 minutes with TBST. The membranes were then incubated with Immobilon
Classico Western HRP Substrate (Millipore Sigma (Oakville, ON) for 5 minutes and images
were captured using the ChemiDoc™ Imaging system (Bio-Rad) and bands were quantified
using Image Lab 4.1 software.

2.5.

Flow Cytometry

Three days following siRNA transfection, cells were detached using 0.53mM EDTA (Wisent
Bioproducts 325-060-EL) and placed in the incubator at 37°C with 5% C02 for 10 minutes, cells
were mechanically dislodged with a P200 pipette and incubated again for 10 minutes. Once cells
are dissociated, 2 mL of FACS Buffer (5% FBS diluted in PBS) was added and cells were
counted (TC10 cell counter, Bio-Rad) to ensure 5 x105 cells were transferred to 1.5 mL
Eppendorf tubes. Samples were centrifuged at 2000rpm for 5 minutes and washed with 150 μL
FACS Buffer. After 2-3x washes and centrifuged, 200 μL of FACS Buffer was added and
incubated with primary AlexaFluor488 αvβ5 anti-human/rat (5 μL, Biolegend) antibody for 1
hour. Samples were washed 2-3x with FACS Buffer and on the last wash, add 50 μL with
fixation Buffer (2% paraformaldehyde diluted in PBS) for 20 minutes. After the samples were
centrifuged, 200 μL of FACS Buffer was added and samples were incubated overnight at 4°C.
Next day, samples were centrifuged and washed 2-3x and 500 μL volumes were strained and
transferred over to flow tubes. Samples were analyzed using an EPICS XL-MCL or Cytomics
FC500 flow cytometer (Beckman Coulter).
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2.6.

Timed Cell Adhesion Assay

Cells were seeded in a 24-well standard tissue culture-treated dish at 200 000 cells per well. At
specific time points determined from previous experiments (Collins & Shepherd, unpublished)
(45 minutes for HEYA8 cells, 4 hours for OVCAR8 cells, 1 hour for FT190, TOV21G and ES-2
cells), non-adherent cells were aspirated, the plate was washed with PBS, then trypsinized and
counted with Trypan Blue to quantify single cell adhesion. Time points were determined using a
time course cell adhesion assay, where single cell adhesion was quantified using Trypan Blue for
all 5 cell lines without transfection. The time points used were: 30 min, 45 min, 1 hour, 2 hours,
3 hours, 4 hours, 5 hours and 6 hours. Cells were counted using TC10 cell counter (Bio-Rad) and
values were normalized to the initial seeding density. The time point at which all cells have
attached was used as the time point comparing siNT and siITGβ5 conditions for each cell line.

2.7.

Determination of Doubling Time

Three days after siRNA transfection cells were seeded in a 48-well adherent culture at a density
of 7500 cells per well. (Essen Bioscience, Ann Arbor, MI), Percent confluence was measured by
Incucyte for 7 days by capturing phase contrast images every 3 hours and taking the average of 9
images. To calculate doubling time, an exponential growth curve was fitted to the confluenceover-time results in Graphpad PRISM.

2.8.

Trypan Blue Exclusion Viability Assay

Three days following siRNA transfection cells were seeded in a 24-well standard tissue culture treated plate at a density of 125 000 cells per well or ultra-low attachment (ULA) plates at a
density of 50 000 cells per well for 24 or 72 hours. Adherent cells were detached using 50 μL
trypsin-EDTA (0.25%) and incubated at 37°C with 5% CO2 for 10 minutes. After adding 100 μL
of FBS, cells were transferred to 1.5 mL Eppendorf tubes and 150 μL of Trypan Blue dye
(ThermoFischer Scientific) was added to each tube. Stained cells were added to the cell counter
slide and viability readings were taken using TC10 cell counter (Bio-Rad).
Spheroids from 24-well ULA plates were transferred to 1.5mL Eppendorf tubes and centrifuged
at 1500rpm for 3 minutes. Media was completely aspirated from tubes avoiding the pelleted
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spheroids at the bottom. Pellets were washed twice with 1mL of PBS, centrifuged again and
media was aspirated. A volume of 50 μL of trypsin-EDTA (0.25%) was added and tubes were
placed in 37°C water bath for 30 minutes with gentle vortex every 10 minutes. After incubation,
100 μL FBS was added to resuspend the dissociated spheroids followed by resuspending in 150
μL of Trypan Blue dye (ThermoFischer Scientific). Once cells were counted using TC10 cell
counter, the total cell number and live cell number were recorded.

2.9.

CellTiter-Glo Spheroid Viability assay

Three days after siRNA transfection cells were seeded in 96-well ULA plate at a seeding density
of 4000 cells per well for 24 or 72 hours. CellTiter-Glo® reagent (Promega) was added to each
well at a volume of 100 μL (1:1 ratio of CellTiter-Glo® reagent and Media in the well). Three
wells for each time point consisted of only media and the CellTiter-Glo® reagent at a 1:1 ratio
(Blank controls). Plates were incubated overnight at -80°C to ensure lysis. The following day
198 μL was transferred from each well into a white-walled 96-well plate. Readings were
measured on Wallac 1420 victor 2 spectrophotometer plate reader, measuring luminescence. The
average luminescence readings for Blank control wells (i.e., media alone) were subtracted from
the luminescence readings from the average per experimental condition.

2.10.

Spheroid Reattachment Assays

Three days following siRNA transfection cells were seeded in 96-well ULA plates at a seeding
density of 4000 cells per well for 24 or 72 hours. The cultured spheroids were then transferred to
48-well adherent culture plates with 1 mL of 10% FBS media and incubated at 37°C with 5%
CO2. Spheroids were permitted to reattach and disperse for an additional 24 hours prior to fixing
and staining using HEMA3 (Fisher, Kalamazoo, MI, USA). Spheroid reattachment and
dispersion areas were calculated using the Trainable Weka segmentation analysis plugin on the
Fiji Image J 2.1 software (NIH). Total spheroid reattachment for full wells was quantified by
creating classifiers that can differentiate between the background well and the stained area of the
reattached spheroid. Once the program has differentiated the image using the classifiers, a black
and white binary image was created in order for the program to calculate the total area for the
regions of interest. Spheroid dispersion area was calculated using the same Trainable Weka
segmentation analysis plugin on the Fiji Image J 2.1 software (NIH) using high magnification
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images. Classifiers were used to differentiate between the background and the stained spheroid
area and a binary image was created to calculate the total spheroid reattachment area for single
spheroids. This process was repeated using 3 different classifiers to differentiate between
spheroid core, dispersing monolayer and well background area and calculate the area for the
reattached spheroid core. Spheroid dispersion was defined as the spheroid core area subtracted
from the total reattached spheroid area for OVCAR8, TOV21G and ES-2. Due to the
morphology of the spheroids of FT190 and HEYA8, this method could not be used. Instead, total
reattached spheroid area was quantified alone.

Spheroid reattachment assays with the ECM-coated plates were completed with spheroids
cultured in 96-well ULA plates at a seeding density of 4000 cells per well for 24 hours.
Spheroids were then transferred to either BSA, fibronectin or vitronectin coated 24-well adherent
culture plates with 1 mL of 0% FBS media and incubated at 37°C with 5% CO2. The fibronectincoated plates were acquired from Corning Life sciences and stored at 4°C until use. The
vitronectin-coated plates were prepared using human recombinant vitronectin (Millipore Sigma,
SRP3186) as per the manufacturer’s guidelines. The BSA-coated plates were prepared by 0.1%
BSA diluted in sterile water. Spheroids were permitted to reattach and disperse for an additional
24 hours prior to fixing and staining using HEMA3. Spheroid reattachment and single spheroid
areas were calculated using the Trainable Weka segmentation analysis plugin on the Fiji Image J
2.1 software (NIH).

2.11.

Statistical Analysis

Statistical analysis was completed using Graphpad PRISM 9 (GraphPad Software, San Diego,
CA). Analyses were performed using two-tailed Student’s t-test and a p-value less than 0.05 was
considered statistically significant (*, p < 0.05; ;**, p < 0.01;***, p < 0.001).
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Chapter 3

3. Results
3.1.

Integrin gene expression in serous ovarian tumours and ovarian
cancer cell lines

To begin, mRNA expression levels of all integrins were evaluated using publicly available
datasets from the from the Cancer Genome Atlas (TCGA). By assessing the expression of the
superfamily of integrins among ovarian cancer tumors and cell lines, we can then evaluate the
expression of integrin β5 within this framework. The data suggests that there is wide variability in
expression of both integrin 𝛼- and β-subunits (Figure 3.1). Interestingly, the expression of
integrin 5 is high relative to other β-subunits in both serous ovarian tumours and cell lines.
Integrin 5 mRNA expression is the third highest β-subunit in the tumours (Figure 3.1A) and
second highest in gene expression among ovarian cancer cell lines (Figure 3.1B). Furthermore,
the 𝛼-subunit associated with integrin 5 to form a functional heterodimer, integrin 𝛼𝑣 also has
relatively high expression and is the second highest 𝛼-subunit expressed in both serous ovarian
tumors (Figure 3.1A) and ovarian cancer cell lines (Figure 3.1B).

3.2.

Integrin β5 is expressed across established ovarian cancer cell lines and
patient-ascites derived cell lines

To further validate the data from TCGA, we sought to evaluate the expression of integrin 5
within well-established cell lines across two subtypes of ovarian cancer: High-grade serous
ovarian cancer cell lines (HGSOC) and clear cell carcinoma cell lines (OCCC). HGSOC is the
most common and most aggressive subtype accounting for 75% of all EOCs [8]. Although early
detection of OCCC has a patient 5-year disease-free survival rate of 86-89%, advanced stage
prognosis is remarkably poorer than that of patients with serous carcinoma [114]. The use of
readily available and well-established cell lines from both subtypes provides appropriate context
for assessing the role of integrin 5 in EOC. Transcript expression data for HGSOC and OCCC
was obtained from the Cancer cell line encyclopedia (CCLE) dataset and the protein expression
was evaluated using western blot analysis with adherent culture day 3 lysates.
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The mRNA expression of integrin 5 is expressed with high variability across multiple HGSOC
and clear cell carcinoma cell lines (Figure 3.2A). When assessing the protein level expression
of integrin 5, it was evident that integrin 5 expression varies across both ovarian cancer
subtypes but is still detectable (Figure 3.2B, 3.2C). The clear cell carcinoma cell lines that have
shown the highest integrin β5 protein expression level were OVMANA and KOC7C whereas,
the SMOV2, TOV21G, ES-2 and 105C show similar yet lower levels (Figure 3.2B, 3.2C). The
HGSOC cell lines that show the highest integrin β5 protein expression are the OVCA 420,
OVCA 433 and OVCAR5 cell lines (Figure 3.2B, 3.2C). The CAOV3, HEYA8 and OVCAR8
cell lines show similar integrin 5 protein expression to the normal fallopian tube immortalized
control cell line, FT190 (Figure 3.2B, 3.2C). The immortalized fallopian tube cell line is used as
a control since it is now widely considered that HGSOC initiates from the secretory epithelial
cells of the distal fallopian tube [26]. The HGSOC cell lines that show very little integrin 5
protein expression are the OVCAR8 and COV362 (Figure 3.2B, 3.2C).
Several early-passage ovarian cancer patient-ascites derived cell lines generated by our
laboratory (G. DiMattia) were also used to evaluate the protein expression of integrin 5 through
western blot analysis. Similar to the established cell lines, the patient-ascites derived cell lines
exhibit detectable integrin 5 protein expression (Figure 3.2D, 3.2E). This overall assessment of
integrin β5 expression among established cell lines enabled us to identify appropriate cell lines
for functional assays using targeted siRNA-mediated knockdown. The cell lines chosen display a
spectrum of integrin β5 expression to account for the differences across cell lines when
evaluating the function of integrin β5 within EOC (Table 3.1).

3.3.

Transient Knockdown of Integrin 5 leads to a decrease in cell
viability of EOC cells in adherent culture

To evaluate the role of integrin 5 within EOC, siRNA-mediated knockdown of ITGβ5 in
OVCAR8, HEYA8, TOV21G and ES-2 cell lines was completed (Figure 3.3). OVCAR8 and
HEYA8 are well established HGSOC cell lines and TOV21G and ES-2 are representative OCCC
cell lines. Based on the previous western blot analysis, HEYA8 have higher protein expression of
integrin 5 than OVCAR8 (Figure 3.2B, 3.2C). Whereas, both TOV21G and ES-2 show similar
protein level expression of integrin β5 (Figure 3.2B, 3.2C). Transient knockdown was also
performed on the FT190 cell line as a control for HGSOC (Figure 3.3). The knockdown of
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Figure 3.1: Integrin 5 has relatively high expression across serous ovarian tumors and cancer cell lines
(A) Integrin family gene expression in serous ovarian tumors and ovarian cancer cell lines (B) obtained from
publicly-available The cancer genome atlas (TCGA) dataset. Integrin 𝛼𝑣 has the second highest alpha subunit gene
expression in ovarian tumors and cancer cell lines. The shading represents the subclasses of I-domain and nonshaded represent non-I domain within 𝛼-subunits.
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Figure 3.2: Integrin 5 transcript and protein expression is detectable across two EOC subtypes and patient
ascites derived cell lines
(A) Transcript expression (transcript per million) was obtained from Cancer Cell line encyclopedia (CCLE) dataset
for clear cell carcinoma and HGSOC cell lines. (B) Representative western blots of integrin β5 protein expression
across both clear cell carcinoma and HGSOC cell lines. The results are presented as the mean±SD. (n=3) (C)
Densitometry analysis shows pixel intensity volume for integrin β5 relative to vinculin across both clear cell
carcinoma and HGSOC cell lines. (D) Representative western blot of integrin β5 across patient ascites derived
iOVCA cell lines. (E) Densitometry analysis shows pixel intensity volume for integrin β5 relative to tubulin. The
results are presented as the mean±SD. (n=3).
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Table 3.1 Summarya of Epithelial ovarian cancer cell lines
Cell line

EOC subtype

FT190

Immortalized normal

Mutations
--

distal fallopian tube

Integrin Interaction
Increased L1CAM expression leads to
increased spheroid formation due to the
upregulation of integrin subunits 𝛼5 and 𝛽1 [3]

OVCAR8

HEYA8

High grade ovarian

CTNNB1,

Increased L1CAM expression leads to

serous adenocarcinoma

ERBB2, KRAS,

increased spheroid formation due to the

TP53

upregulation of integrin subunits 𝛼5 and 𝛽1 [3]

BRAF, KRAS

Treating with integrin subunit 𝛽1 blocking

High grade ovarian
serous adenocarcinoma

antibody MAB13 leads to spheroid
disaggregation [4]
Increased 𝛼2 and decreased 𝛼6 integrin subunit
expression was observed in spheroids [5]
The use of anti-αvβ3 Etaracizumab leads to
decreased tumor burden in xenograft mouse
model [6]

TOV21G

ES-2

a

Ovarian clear cell

KRAS, PIK3CA,

adenocarcinoma

PTEN

Ovarian clear cell

BRAF, PALB2,

adenocarcinoma

TERT, TP53

--

--

Data presented in table obtained for Cancer cell line encyclopedia (CCLE) dataset for

information on subtype and mutations.
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ITGβ5 was initially validated through western blot analysis using an antibody against integrin β5
(Figure 3.3A). As a method of additional validation, flow cytometry using an antibody for the
heterodimer αv5 was performed which shows that knocking down ITGβ5 leads to an 80-85%
decrease in the expression of the functional heterodimer (Figure 3.3B, 3.3C). Our results suggest
FT190, HEYA8, ES-2 and TOV21G have a higher level of knockdown than OVCAR8 (Figure
3.3B, 3.3C). This could be attributed to the already low expression of integrin β5 in the
OVCAR8 (Figure 3.2B, 3.2C).
Cell viability assays were completed to assess the viability of knockdown in adherent conditions.
To evaluate the viability of cells, Trypan blue exclusion counting was conducted at both 24 and
72 hours. The results indicate that ITGβ5 knockdown significantly decreased the number of
viable cells in adherent culture for FT190 at 24 hours and OVCAR8 cells at both 24 and 72 hours
(Figure 3.3D, 3.3E). Although no significant difference in viability is detected in OCCC cell
lines TOV21G and ES-2 at 24 hours, there is a significant decrease in cell viability at 72 hours
(Figure 3.3D, 3.3E). Interestingly, the HEYA8 cells showed no significant difference in relative
cell viability at 24 hours but by 72 hours, there was a significant increase in the number of viable
cells (Figure 3.3D, 3.3E). Altogether, it seems that the loss of integrin β5 impacts cell viability in
adherent culture as early as 24 hours in culture.

3.4.

Integrin β5 knockdown decreases cell adhesion in EOC without
altering cell proliferation

Integrins pose as critical regulators of cancer cell adhesion therefore we sought to evaluate the
role of integrin β5 as a cell adhesion receptor in EOC. Cell adhesion assay was quantified in
adherent culture at an appropriate time as determined by time course analysis for each cell line.
Single cell adhesion was quantified using Trypan blue cell counting. The loss of integrin β5 in
FT190, OVCAR8 and TOV21G shows a significant decrease in the ability of these cells to attach
to standard tissue culture-treated substratum (Figure 3.4A, 3.4B). Interestingly, integrin 5
knockdown appeared to promote OVCAR8 cells to form spontaneous cell clusters rather than
adhere to the tissue culture plastic. This phenotype was also evident in the other HGSOC cell
line, HEYA8 but to a lesser degree. There is no significant change in the ability of HEYA8 and
ES-2 cells to attach when ITGβ5 is knocked down (Figure 3.4A, 3.4B). To assess whether the
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altered adhesion affects proliferation rate, cell doubling time analyses were completed. The
results indicate that there is no significant change in doubling times between the control and
knockdown conditions among all cell lines (Figure 3.4C). Overall, the results suggest that the
knockdown of ITGβ5 decreases the cell adhesion of FTE cells and the majority of EOC cell
lines.

3.5.

Transient knockdown of Integrin β5 impacts spheroid viability

As a next step, it was important to evaluate β5 integrin function in anchorage-independent
conditions since this is a critical step in EOC metastasis. After siRNA-mediated knockdown of
ITGβ5, spheroid viability analysis was performed by Trypan blue exclusion cell counting using a
TC10 automated cell counter. The loss of integrin β5 does not result in any overt change in spheroid
phenotype compared to control (Figure 3.5A). Although there is so significant change in spheroid
viability from integrin 5 knockdown in normal FT190 cells at 24 hours, there is a significant loss
of viable cells by 72 hours in suspension culture (Figure 3.5B, 3.5C). OVCAR8 cells exhibited a
decrease in spheroid viability at 24 hours from the loss of integrin β5, however, this decrease is not
sustained at 72 hours (Figure 3.5B, 3.5C). Similarly, ES-2 cells have a significant decrease in
spheroid viability at 24 hours and continue to have a decreased trend in the number of viable cells
at 72 hours (Figure 3.5B, 3.5C). Interestingly, there is a significant increase in the number of
viable HEYA8 cells at 72 hours and TOV21G cells in spheroid culture at both 24 and 72 hours
(Figure 3.5B, 3.5C). CellTiter-Glo Luminescence cell viability assay was used as an additional
method to assess spheroid cell viability based upon ATP as an indicator of metabolically-active
viable cells. As indicated by previous spheroid viability results, ITGβ5 knockdown results in a
significant increase in the average luminescence in TOV21G cells (Figure 3.5D). However, all
other cells lines showed no difference in spheroid cell viability based on CellTiter-Glo assay
(Figure 3.5D).
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Figure 3.3: Transient knockdown of integrin 5 leads to a decrease in cell viability of EOC cells in adherent
culture
(A) Immunoblot analysis validating ITGβ5 knockdown in FT190, OVCAR8, HEYA8 TOV21G, ES-2. Tubulin is
used as a loading control. (B) Flow cytometry analysis of the ITGβ5 knockdown in FT190, OVCAR8, TOV21G and
ES-2 cells transfected with control siNT or siITGβ5 using αvβ5-antibody. (C) The average αvβ5 fluorescence of cells
was calculated. The results are presented as the mean±SD. Analysis was performed using two-tailed student’s t-test
(****, P < 0.0001; ***, P < 0.001) (n=3). (D) Cell viability for FT190, OVCAR8, HEYA8, TOV21G and ES-2
siNT and siITGβ5. Viable cell number was determined by Trypan blue exclusion cell counting at 24 and (E) 72
hours in adherent culture. Data is presented as viable cell number normalized to their respective controls. Analysis
was performed using two-tailed student’s t-test (NS= not significant;*, P < 0.05;**, P < 0.01; ***, P < 0.001) .
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Figure 3.4: Integrin β5 knockdown decreases cell adhesion in EOC without altering cell proliferation
(A) Images of FT190, OVCAR8, HEYA8, TOV21G, ES-2 siNT control and siITGβ5 cultured for 24 hours in
adherent culture plates. Scale bars 200 μm. Images were captured using Leica light microscope (n=3). (B) Single
cell adhesion was quantified with Trypan blue cell counting for FT190, OVCAR8, HEYA8, TOV21G and ES-2 si
ITGβ5 and matched controls. Analysis was performed using two-tailed student’s t-test (*, P < 0.05) (n=3). (C)
Doubling time for FT190, OVCAR8, HEYA8, TOV21G and ES-2 cells transfected with siNT or siITGβ5. Incucyte
Zoom Imaging system measured percent confluence over 7 days. Graphpad PISM was used to generate growth
curves and non-linear regression analysis calculated doubling time. (NS= not significant). (n=3). Graphpad PRISM
was used to generate growth curves and non-linear regression analysis calculated doubling time. (NS= not
significant). (n=3).
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Figure 3.5: Transient knockdown of integrin 5 impacts spheroid viability
(A) Images of FT190, OVCAR8, HEYA8, TOV21G and ES-2 siNT and siITGβ5 in spheroid culture for 24 hours.
Scale bars 500 μm. Images were captured using Leica light microscope (n=3) (B) Spheroid viability for FT190,
OVCAR8, HEYA8, TOV21G and ES-2 siNT and siITGβ5. Viable cell number was determined by Trypan blue
exclusion cell counting at 24 hours and (C) 72 hours. Data is presented as viable cell number normalized to their
respective controls. Analysis was performed using two-tailed student’s t-test (NS= not significant;*, P < 0.05; ;**, P
< 0.01;***, P < 0.001) (n=3). (D) Spheroid viability for FT190, OVCAR8, HEYA8, TOV21G and ES-2 siNT and
siITGβ5. Average luminescence was determined by CellTiter-Glo assay 24 and 72 hours after transfection. Data is
presented as absolute viable cell number. The results are presented as the mean±SD. (*, P < 0.05) (n=3)
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3.6.

Loss of integrin β5 decreases spheroid reattachment in OVCAR8
spheroids and impacts subsequent cell spreading in multiple EOC
cells

To evaluate the role of integrin 5 in a model of secondary metastasis, cell lines that were
transfected with either control or siITGβ5 were seeded to form spheroids. Spheroids were collected
at 24 and 72 hours to perform re-attachment to tissue culture-treated plates. The loss of integrin 5
results in no significant difference in relative spheroid reattachment for FT190, HEYA8, TOV21G,
and ES-2 spheroids at both 24 (Figure 3.6A, 3.6B) and 72 hours (Figure 3.6A, 3.6C). Although
there is a decreasing trend of spheroid reattachment in TOV21G and ES-22, there is an increasing
trend in spheroid reattachment in HEYA8 spheroids at both time points (Figure 3.6B, 3.6C).
Surprisingly, OVCAR8 cells show a dramatic decrease in the ability of spheroids to reattach at
both 24 and 72 hours due to ITGβ5 knockdown (Figure 3.6A, 3.6B, 3.6C).

In addition to quantifying total spheroid reattachment within an entire well, we investigated the
change in spheroid area for individual reattached spheroids. Dispersion area was calculated by
subtracting the spheroid core area from the total spheroid area as determine using Image J FIJI
segmentation plugin. However, FT190 and HEYA8 spheroids do not have a measurable spheroid
core so it was not possible to calculate dispersion area using this method (Figure 3.6D). For these
two cell lines, the quantification for single spheroids is shown as total reattached spheroid area.
The FT190 reattached spheroids show no difference in spheroid area at 24 hours (Figure 3.6D,
3.6E), but there is a significant decrease in spheroid area at 72 hours in the ITGβ5 knockdown
condition (Figure 3.6D, 3.6F). At 24 hours, both OVCAR8 and ES-2 show a significantly
decreased ability of cells to disperse from the spheroid core once attached to tissue culture-treated
substratum (Figure 3.6D, 3.6E). Although OVCAR8 spheroids are larger is size after 72 hours of
spheroid culture, the altered ability of cells to disperse is still evident due to the loss of integrin 5
(Figure 3.6D, 3.6F). Although there was no significant difference in dispersion area for TOV21G
reattached spheroids at both time points and for ES-2 at 72 hours, there was a change in spheroid
morphology (Figure 3.6D, 3.6E, 3.6F). Interestingly, HEYA8 reattached spheroids have a
significantly larger spheroid area when integrin 5 is knocked down at both 24 and 72 hours
(Figure 3.6D, 3.6E, 3.6F). The loss of integrin 5 within the HEYA8 spheroids, exhibited a similar
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change in cell phenotype as seen with TOV21G and ES-2 in addition to an intensive spheroid core
(Figure 3.6D).

3.7.

Decrease in spheroid reattachment and cell spreading in OVCAR8
spheroids associated with integrin 5 and vitronectin interaction

A critical step in secondary tumor formation is the integrin-mediated binding of EOC cells to
mesothelial cells and the underlying ECM. We assessed the interaction of integrin 5, and its
associated αv integrin subunit capable of binding with RGD associated ECM ligands fibronectin
and vitronectin [15], while bovine serum albumin (BSA) was used as a negative control. Similar
to previous spheroid reattachment assay, spheroids for each cell line were cultured in ultra-low
attachment plates for 24 hours transferred spheroids to ECM-coated adherent culture plates for
24 hours. The results indicate that knocking down ITGβ5 does not impact spheroid reattachment
to either the negative control or fibronectin for FT190 (Figure 3.6A), OVCAR8 (Figure 3.6B),
HEYA8 (Figure 3.6C) and TOV21G (Figure 3.6D). The results did indicate a significant
decrease in the ability of OVCAR8 spheroids to reattach in vitronectin-coated wells when ITGβ5
is knocked down (Figure 3.6B). However, this change due to ITGβ5 knockdown in spheroid
reattachment with vitronectin was not evident in FT190 (Figure 3.6A), HEYA8 (Figure 3.6C)
and TOV21G (Figure 3.6D). These results indicate that integrin 5 may play a role in spheroid
reattachment when interacting with vitronectin in OVCAR8 cells.
To investigate the change in subsequent cell spreading after spheroid reattachment seen in
previous spheroid reattachment experiment, we assessed the interaction of integrin 5 with ECM
ligands fibronectin, vitronectin and BSA. There was no significant difference in subsequent cell
spreading in FT190 (Figure 3.8A), HEYA8 (Figure 3.8C), TOV21G (Figure 3.8D) spheroids
when adhering to BSA, fibronectin and vitronectin coated wells. Interestingly, loss of integrin 5
resulted in more dense reattached HEYA8 spheroids under both fibronectin and vitronectin
conditions (Figure 3.8C). The results did indicate a dramatic decrease in the ability of OVCAR8
cells to spread from the reattached spheroid core when the wells were coated with vitronectin
(Figure 3.8B).
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Figure 3.6: Loss of integrin 5 decreases spheroid reattachment in OVCAR8 and impacts subsequent cell
spreading in multiple EOC cells
(A) Spheroid reattachment Hema-3 stained Images of FT190, OVCAR8, HEYA8, TOV21G and ES-2 siNT and
siITGβ5 in spheroid culture for 24 and 72 hours. Images were captured using Axio zoom microscope 9.8x (n=3) (B)
Relative spheroid reattachment total area quantification for FT190, OVCAR8, HEYA8, TOV21G and ES-2 siNT
and siITGβ5 at 24 hours. Total area was determined by Image J Segmentation Plugin analysis. Data is presented as
total stained area and normalized to their respective controls. Analysis was performed using two-tailed student’s ttest (NS= not significant;*, P < 0.05). The results are presented as the mean±SD. (n=3). (C) Relative spheroid
reattachment total area quantification for FT190, OVCAR8, HEYA8, TOV21G and ES-2 siNT and siITGβ5 at 72
hours. Total area was determined by Image J Segmentation Plugin analysis. Data is presented as total stained area
and normalized to their respective controls. Analysis was performed using two-tailed student’s t-test (NS= not
significant;**, P < 0.01). The results are presented as the mean±SD. (n=3). (D) High magnification spheroid
reattachment Hema-3 stained Images of FT190, OVCAR8, HEYA8, TOV21G and ES-2 siNT and siITGβ5 in
spheroid culture for 24 and 72 hours. Scale bar FT190 and OVCAR8 200 μm. Scale bar HEYA8, TOV21G and ES2 500 μm. Images were captured using Leica light microscope (n=3). (E) Relative spheroid dispersion area
quantification for FT190, OVCAR8, HEYA8, TOV21G and ES-2 siNT and siITGβ5 at 24 hours. FT190 and
HEYA8 spheroid area was determined by quantifying total area of the reattached spheroid. Dispersion area was
determined by subtracting spheroid core area from the total area of the spheroid using Image J Segmentation Plugin
analysis. Data is presented normalized to their respective controls. Analysis was performed using two-tailed
student’s t-test (NS= not significant;*, P < 0.05; ;**, P < 0.01). The results are presented as the mean±SD. (n=3).
(F) Relative spheroid dispersion area quantification for FT190, OVCAR8, HEYA8, TOV21G and ES-2 siNT and
siITGβ5 6 at 72 hours. FT190 and HEYA8 spheroid area was determined by quantifying total area of the reattached
spheroid. Dispersion area was determined by subtracting spheroid core area from the total area of the spheroid using
Image J Segmentation Plugin analysis. Data is presented normalized to their respective controls. Analysis was
performed using two-tailed student’s t-test (NS= not significant;*, P < 0.05). The results are presented as the
mean±SD. (n=3).
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Figure 3.7: Decrease in spheroid reattachment in OVCAR8 spheroids associated with integrin 5 and
vitronectin interaction
(A) Spheroid reattachment Hema-3 stained Images of FT190 siNT and siITGβ5 using either Bovine Serum Albumin
(BSA), fibronectin or vitronectin coated adherent tissue culture plates at 24 hours. Images were captured using Axio
zoom microscope at 6.6x. Relative spheroid reattachment total area quantification for FT190 siNT and siITGβ5 at 24
hours. Total area was determined by Image J Segmentation Plugin analysis. Data is presented as total stained area
and normalized to their respective controls. Analysis was performed using two-tailed student’s t-test. The results are
presented as the mean±SD. (n=3). (B) Spheroid reattachment Hema-3 stained Images of OVCAR8 siNT and
siITGβ5 using either BSA, fibronectin or vitronectin coated adherent tissue culture plates at 24 hours. Images were
captured using Axio zoom microscope at 6.6x. Relative spheroid reattachment total area quantification for OVCAR8
siNT and siITGβ5 at 24 hours. Total area was determined by Image J Segmentation Plugin analysis. Data is
presented as total stained area and normalized to their respective controls. Analysis was performed using two-tailed
student’s t-test (*, P < 0.05). The results are presented as the mean±SD. (n=3). (C) Spheroid reattachment Hema-3
stained Images of HEYA8 siNT and siITGβ5 using either BSA, fibronectin or vitronectin coated adherent tissue
culture plates at 24 hours. Images were captured using Axio zoom microscope at 6.6x. Relative spheroid
reattachment total area quantification for HEYA8 siNT and siITGβ5 at 24 hours. Total area was determined by
Image J Segmentation Plugin analysis. Data is presented as total stained area and normalized to their respective
controls. Analysis was performed using two-tailed student’s t-test. The results are presented as the mean±SD. (n=3).
(D) Spheroid reattachment Hema-3 stained Images of TOV21G siNT and siITGβ5 using either BSA, fibronectin or
vitronectin coated adherent tissue culture plates at 24 hours. Images were captured using Axio zoom microscope at
6.6x. Relative spheroid reattachment total area quantification for HEYA8 siNT and siITGβ5 at 24 hours. Total area
was determined by Image J Segmentation Plugin analysis. Data is presented as total stained area and normalized to
their respective controls. Analysis was performed using two-tailed student’s t-test. The results are presented as the
mean±SD. (n=3).
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Figure 3.8: Decrease in subsequent cell spreading after reattachment in OVCAR8 spheroids is associated with
integrin 5 and vitronectin interaction
(A) High magnification spheroid reattachment Hema-3 stained Images of FT190 siNT and siITGβ5 on BSA,
fibronectin, and vitronectin coated plates for 24 hours. Scale bar 500 μm. Images were captured using Leica light
microscope (n=3). Absolute spheroid area quantification for FT190 siNT and siITGβ5 at 24 hours. Total area was
determined by Image J Segmentation Plugin analysis. Data is presented as total reattached spheroid area. Analysis
was performed using two-tailed student’s t-test. The results are presented as the mean±SD. (n=3). (B) High
magnification spheroid reattachment Hema-3 stained Images of FT190 siNT and siITGβ5 on BSA, fibronectin, and
vitronectin coated plates for 24 hours. Scale bar 500 μm. Images were captured using Leica light microscope (n=3).
Absolute spheroid area quantification for FT190 siNT and siITGβ5 at 24 hours. Total area was determined by Image
J Segmentation Plugin analysis. Data is presented as total reattached spheroid area. Analysis was performed using
two-tailed student’s t-test. The results are presented as the mean±SD. (n=3). (C) Spheroid reattachment Hema-3
stained Images of HEYA8 siNT and siITGβ5 using either BSA, fibronectin or vitronectin coated adherent tissue
culture plates at 24 hours. Scale bar 500 μm. Images were captured using Leica light microscope (n=3). Relative
spheroid reattachment total area quantification for HEYA8 siNT and siITGβ5 at 24 hours. Total area was determined
by Image J Segmentation Plugin analysis. Data is presented as total stained area and normalized to their respective
controls. Analysis was performed using two-tailed student’s t-test. The results are presented as the mean±SD. (n=3).
(D) Spheroid reattachment Hema-3 stained Images of TOV21G siNT and siITGβ5 using either BSA, fibronectin or
vitronectin coated adherent tissue culture plates at 24 hours. Scale bar 500 μm. Images were captured using Leica
light microscope (n=3). Relative spheroid reattachment total area quantification for HEYA8 siNT and siITGβ5 at 24
hours. Total area was determined by Image J Segmentation Plugin analysis. Data is presented as total reattached
spheroid area and normalized to their respective controls. Analysis was performed using two-tailed student’s t-test.
The results are presented as the mean±SD. (n=3).
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Chapter 4

4. Discussion
4.1.

Summary of findings

My thesis provides insight into the previously unknown role of integrin 5 in EOC. We have
shown that integrin 5 mRNA expression is detectable across serous ovarian tumours and cell
lines. The protein expression of integrin 5 varies across numerous well-established cell lines and
patient-ascites derived cell lines. Previously, Kaplan-Meier analysis has shown that elevated
integrin 5 levels in ovarian cancer are significantly associated with decreased patient survival
and increased immunohistochemistry staining of integrin 5 in advanced stages II-IV compared
to normal ovary tissue and stage I serous tumors [91]. My transient knockdown data indicates
that there is a decrease in cell viability within adherent culture across multiple EOC cell lines.
Alongside the change in viable cell number, there was a significant decrease in the ability of
cells to adhere to tissue culture substratum. The results indicate that there is no change in
proliferation rate for all cell lines evident through the doubling time analysis. When studying
spheroids derived from EOC cell lines, we show that there is no visible change in spheroid
morphology when integrin 5 is knocked down. Although our results indicate a decrease in
spheroid viability in three of the five cell lines, there is also a significant increase in the number
of viable cells in the other two cell lines. To further explore the role of integrin 5 in EOC, we
evaluated the role of integrin 5 in spheroid reattachment. The results indicate that the ability of
OVCAR8 spheroids to reattach and cell dispersion is significantly decreased. Alternatively, there
is an increase in the dispersion area of HEYA8 spheroids although there was no change in the
ability of these spheroids to reattach. Perhaps spheroid viability contributes to the ability of
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spheroids to reattach and then disperse. Spheroid viability data suggests that knockdown of
integrin 5 leads to decreased OVCAR8 spheroid viability whereas, HEYA8 spheroids have
increased viability. Lastly, we investigated the role of integrin 5 in integrin-mediated EOC
spheroid reattachment to various ECM ligands. The results demonstrate that the decrease in
OVCAR8 spheroid reattachment and subsequent cell spreading is associated with integrin 5—
vitronectin interaction.

4.2.

Integrin 5 knockdown decreases cell adhesion in EOC

Cell adhesion interactions are involved in numerous physiological processes such as wound
healing and embryonic development as well as the progression of diseases such as cancer [115].
One of the best characterized cell adhesion receptors are integrins, which can play a critical role
in cell-cell or cell-matrix interactions [3, 4] . Integrins can assemble various forms of cell-matrix
adhesion such as clustering in focal adhesions and the formation of a mechanical link between
ECM and intracellular actin bundles [3, 4]. The physical interaction link between cells and ECM
proteins are the reason integrins are considered mechanosensing receptors [118]. The first step
of mechanosensing is the conformation change of integrins by moving from a low to high
affinity conformation through outside-in or inside-out signaling to form integrin clusters on the
membrane [118]. Previously, it has been demonstrated there is an enrichment of integrin 5 to
specific adhesion structures during interphase when analyzing cell cycle stages [119]. In our
study, we showed that the transient knockdown of integrin 5 leads to a significant decrease in
the ability of FT190, OVCAR8 and TOV21G cells to attach to tissue substratum. These results
may reflect on the change in signal transductions from the loss of integrin 5 and disruption of
cell adhesion interactions.
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One aspect of cell detachment is facilitated by integrin-mediated upregulation of MMPs
and activation of EMT [36]. For instance, the clustering of α2β1 and α3β1 enables the induction
of MMP9 that leads to E-cadherin cleavage and cell-cell adhesion loosening through an Src
kinase-dependent manner [54]. Increased MMP9 expression in ovarian tumor tissues and ascites
has been associated with disease reoccurrence and poor patient survival [120]. Src family kinases
are involved in integrin-mediated signal transmission from the extracellular environment via
FAK activation [121] or through  integrin cytoplasmic tail that can induce Src activation [122].
Current data has shown that inhibition of Src activity can block integrin-induced E-cadherin
ovarian cancer cell dissociation [54]. Furthermore, the loss of cell adhesion to the substratum has
been defined as anoikis, a form of cell death [123]. However, the use of an αv integrin blocking
antibody was not associated with cell death despite the alteration of cell adhesion [45]. The
inhibition of αv integrins resulted in detachment of IGROV1 cells from the substratum and
altered SKOV-3 cell spreading [45]. There was also a decrease in cell growth and cell cycle
progression from the αv integrin blockade [45]. This was associated with an inhibition of ILK
activity and subsequent inhibition of PKB/Akt phosphorylation on serine-473 and upregulation
of p27Kip1 [45]. Interestingly, our results differed regarding cell growth since we have shown that
there is no significant change in doubling time across all five cell lines. This difference could be
attributed to the fact that Cruet-Hennequart et al. measured proliferation by counting cells after a
48 hour treatment with αv integrin blocking antibody [45] whereas we calculated doubling time
by measuring percent confluency over a 7 day period post transfection. Furthermore, our study
focuses on knocking down only one of the αv integrins and so perhaps the loss of multiple αv
integrins leads to an additive effect and the loss of only integrin 5 could be compensated by
other αv integrins. Although there was a similar phenotype of cell detachment seen from the loss
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of integrin 5 in OVCAR8 in adherent culture, this phenotype was not further investigated.
Therefore, it may be worth further exploration to evaluate the altered cell adhesion interactions.

4.3.

Loss of Integrin 5 decreases spheroid reattachment in OVCAR8
spheroid and impacts subsequent cell spreading in multiple EOC cells
EOC metastasis occurs through multicellular disaggregates, known as spheroids, which

exfoliate from the primary tumor and can reattach at another location within the peritoneum or
omentum to form a secondary tumor [5]. This form of metastasis suggests that cell-cell and cellmatrix mechanisms regulate EOC progression and therefore it is critical to understand the
interactions leading to spheroid reattachment and invasion of the mesothelium [5]. Our results
indicate that the transient knockdown of integrin 5 leads to a dramatic decrease in spheroid
reattachment and subsequent spheroid disaggregation on the cell culture plate substratum.
Although, there was no significant change in spheroid reattachment among the other cell lines,
there was also a decrease in single spheroid reattachment area with the FT190 at 72 hours.
However, there was a significant increase in the spheroid dispersion area for the HEYA8
spheroids when integrin 5 was knocked down. One aspect of the decrease in spheroid
reattachment and subsequent spheroid reattachment could be attributed to the decrease in
spheroid viability due to loss of integrin 5 for the OVCAR8 and FT190 spheroids. Interestingly,
HEYA8 spheroids have shown an increase in spheroid viability and spheroid disaggregation post
reattachment. These results could suggest that changes in spheroid viability may contribute to
spheroid reattachment.
Furthermore, the previous literature highlights the importance of EMT and change in the
expression of various integrins could lead to changes in spheroid reattachment. For instance, the
loss of E-cadherin leads to transcriptional upregulation of fibronectin and α5β1 integrin, which is
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essential when spheroids initiate adhesion at a secondary site [53]. Interestingly, Bianchi et al.
have demonstrated that the β-subunits associated with 𝛼𝑣 integrins are upregulated during TGF-β
induced EMT in breast carcinoma [58]. Specifically, knockdown of integrin 5 blocks the EMT
response to TGF-β which impairs the assembly of tight junctions and formation of cell-matrix
adhesion structures in mouse and human mammary epithelial cell lines [58]. This suggests that
integrin 5 cell-matrix adhesion interactions play a role in EMT process in response to TGF-β
and the tumorigenic potential of carcinoma cells [58]. We have previously established that TGFβ activity is induced during ascites-derived EOC spheroid formation indicated by the
upregulation of Snai1, Twist1, Twist2 and Zeb2 mesenchymal markers [57]. When spheroids
were treated with either TGF-β receptor 1 inhibitor or DMSO control, there was reduced cell-cell
cohesion within spheroids and a decrease in spheroid dispersion area [57]. The enhanced
epithelial phenotype of dispersing cells treated with TGF-β inhibitor compared to the control
may have contributed to the decrease in cell motility after reattachment. Similar to breast
carcinoma [58], it may be possible that the regulation of integrin 5 expression and TGF-β
induced EMT in EOC may impact spheroid reattachment and subsequent cell spreading. Since
our previous work has shown the role of TGF-β activity in EOC spheroid formation and
reattachment, it is important that future studies focus on elucidating a possible association of
integrin 5 and TGF-β induced EMT.

4.4.

Decrease in spheroid reattachment and disaggregation in OVCAR8
spheroids associated with Integrin 5 and vitronectin interaction
A critical step in secondary tumor formation is the integrin-mediated binding of EOC

cells to the underlying ECM of the mesothelial layer. Many studies have shown that integrin 1
is a critical beta subunit since it can pair with a variety of alpha subunits and participate in EOC
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cell attachment and migration on ECM substrata relevant to peritoneal metastasis [5]. This
association has been seen in gastric cancer cells as well, where peritoneal invasion was inhibited
by blocking integrin α21 association with collagen I and discouraging cancer cell attachment
[124]. Our results indicate that knocking down integrin 5 results in a significant decrease in the
ability of OVCAR8 spheroids to reattach and disaggregate on vitronectin-coated substrata.
However, there was no significant difference in OVCAR8 spheroid reattachment to fibronectin
or BSA. Although this potential role of integrin 5 has not been seen in EOC previously, the
inhibition of other integrins has been associated with altered spheroid disaggregation. The
inhibition of collagen-associated integrin α21 lead to attenuated spheroid disaggregation on
artificial ECM [8,19, 20]. Burleson et al. have also shown that integrin 1 partially mediates
adhesion of EOC spheroids to ECM and plays a more significant role in spheroid disaggregation
[61]. When evaluating spheroid disaggregation on ECM-coated surfaces, the addition of an
inhibitory antibody against integrin 1, eliminated OVCAR5 spheroid disaggregation on laminin,
fibronectin and type-IV collagen to an extent and a 50% reduction on collagen I [61]. Although
our results also indicated a significant decrease in the ability of OVCAR8 spheroids to reattach
to a vitronectin-coated surface, integrin 1 blockade did not prevent initial spheroid reattachment
[61].
Interestingly, the loss of integrin 5 did not prevent spheroid reattachment or
disaggregation in the other EOC cell lines. It is known that integrins can play different roles in
cell fate decisions. For instance, two gastric adenocarcinoma sublines differ in their response to
anchorange-independent culture where one results in apoptosis and the other results in cell cycle
arrest [125]. Our results indicate that inhibiting the interaction between integrin 5 and
vitronectin impacts spheroid reattachment and disaggregation in the OVCAR8 but does not seem
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to affect the other cell lines. Perhaps this can be attributed to the varying expression of other αv
integrins across these cell lines. For instance, it may be possible that another αv integrin capable
of binding with vitronectin is compensating for the loss of integrin 5 and is able to engage in
signaling pathways allowing for continued spheroid reattachment and subsequent cell spreading.
Kligys et al. have shown that α6β4 is a master regulator of transcription and translation of other
integrin subunits and the loss of this heterodimer can decrease the expression of α2 and α3
integrin subunits [126]. They provide evidence that the α6β4 integrin-dependent signaling via
phosphorylation of 4EBP1 and activation of PI3K regulates the translation of other integrin
subunits such as α3 [126]. While αv integrins also interact with vitronectin as an ECM ligand, it
does not imply that the cell-matrix adhesions will lead similar changes in cell motility. The
difference in cell migration between two ECM-binding integrin can involve different signaling
and/or adaptor proteins interacting with differing amino acid sequences on the cytoplasmic tails
of integrin subunits [127]. In this study, we have knocked down integrin 5, however other beta
subunits that bind with αv integrin can differ in their cytoplasmic tail and recruit varying adaptor
proteins forming a different signaling platform [127]. Overall, altering the expression of integrins
and their composition of cell-matrix adhesion complexes may be a driving force in cancer
progression processes.

4.5.

Limitations of current study
My work helped to begin the process of uncovering the function of integrin 5 in EOC,

however there are some aspects of the study that have limitations. This can be explored and
addressed further through additional experimentation.
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Firstly, the single cell adhesion assays in adherent culture showed that some cell lines, the
loss of integrin 5 led to the formation of spontaneous cell clusters that were suspended in the
media. Previous literature has shown that these cell clusters can form by budding directly from a
monolayer where budding was associated with vertical growth, continued cell-cell interactions
and eventual release of the cell cluster [34]. Pease et al. reveal that the cell lines capable of
forming these cell clusters in adherent culture showed a lack of E-cadherin at cell-cell borders
and the presence of vimentin filaments throughout the cytoplasm through immunofluorescence,
indicating the cells have undergone EMT [34]. To evaluate the altered cell adhesion properties
between the cells in monolayer and the cell clusters in the media, it may be helpful to collect the
supernatant with the cell clusters separate monolayer to perform microarray analysis. This may
provide insight into changes in gene expression from the transient knockdown of integrin 5
between the cell clusters and monolayer. Furthermore, comparing the supernatant lysates with
the monolayer using western blot analysis to probe for EMT associated proteins may provide
advantageous in further evaluating the role of integrin 5 and cell adhesion interactions.
In addition, the spheroid reattachment experiments provided valuable insight into the
function of integrin 5 in secondary metastasis and the interaction with ECM proteins. Our study
shows that the interaction between integrin 5 and vitronectin is important for OVCAR8
spheroid reattachment and subsequent cell spreading. However, there are multiple aspects of
secondary metastasis that ultimately reinforce locally invasive behaviour of EOC such as, ECM
stiffness that increases integrin signaling and subsequent activation of associated pathways [128].
A study by McKenzie et al. investigated the tumor microenvironment that regulates EOC
morphology, migration and spheroid disaggregation using polymer hydrogels with elastic
properties that mimic those of the peritoneum [128]. The peritoneum represents a major target
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for EOC dissemination and polyacrylamide hydrogels that were fabricated with physiologically
appropriate ECM stiffness serve as experimentally relevant adhesive substrates [128]. These gels
can then be coated with different ECM proteins and can help to evaluate EOC cell size, actin
cytoskeletal organization and focal adhesion morphology through immunofluorescence [128].
Moreover, this method provides a physiologically relevant model of the peritoneum to evaluate
spheroid reattachment and disaggregation. Alternatively, Kenney et al. have established a 3D
model of the key components of the omental microenvironment, mesothelial cells, fibroblasts
and ECM, to study ovarian cancer cell adhesion and invasion [129]. They provide evidence that
omental mesothelial cells inhibit, while omental fibroblasts and underlying ECM enhance the
attachment and invasion of EOC cells [129]. The use of this model provides the ability to study
EOC spheroid attachment and disaggregation in the context of the microenvironment which is
critical in EOC metastasis.
Furthermore, it is critical to understand integrin crosstalk and the diverse number of
compensatory mechanisms involved. Our work focuses on investigating the function of integrin
5 and we have assessed this through siRNA-mediated knockdown. However, this integrin
subunit is only one of another 7 beta subunits and 18 alpha subunits. Integrins possess an innate
characteristic where the change in the expression of integrin subunits or the activation of certain
integrins can interfere with the expression or activation of another [130]. For instance, the
expression of integrin α3 decreases the activation of αv, while inhibiting integrin α3 leads to the
activation of αvβ3 expression in several cancer cell types [131]. Furthermore, in the melanoma
cell line MDA-MB-435S which expresses integrins 3 and 5, the knockdown of 3 or 5,
upregulates αvβ5 and αvβ3 respectively [132]. Therefore, western blot analysis to explore whether
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other αv integrins are engaging in compensation mechanisms when integrin 5 is knocked down
may provide insight into the different phenotypes observed across the cell lines.
Lastly, spheroid formation and subsequent reattachment is an essential step in EOC
metastatic cascade. To mimic spheroid formation and subsequent reattachment in this study, a
3D spheroid culture model was used to form spheroids in ULA. These spheroids were then
reattached in adherent culture plates to mimic secondary tumor formation. When completing
these experiments, the spheroids were reattached in media contained FBS. For in vitro cell
expansion, ECM components of FBS as well as other materials of animal origin are required for
cell culture [31]. The use of 10% FBS when completing the spheroid reattachment assays is a
limitation of the experiment since the ECM components within the media can coat the plastic
surface of the well and play a role on cell adhesion. In the future, the use of cell culture media
without FBS in spheroid reattachment assays can address this restriction. This limitation was
addressed going forward in the spheroid reattachment assays with ECM-coated wells where the
spheroids were reattached in media with no FBS.

4.6.

Overall Conclusions
My work has contributed to the growing literature evaluated the role of the integrin

family in cancer progression. I have shown that integrin 5 may play a role in EOC and
knockdown of this beta subunit decreases cell adhesion across multiple cell lines. Furthermore,
the results indicate that the loss of integrin 5 has a dramatic impact on spheroid reattachment
subsequent cell spreading in the OVCAR8 cell line. OVCAR8 is a HGSOC cell line that has
rapid tumor formation ability and for intraperitoneal injections in a xenograft mouse model,
100% tumor take has been seen [32]. Compared to the other OVCAR cell lines, OVCAR8 is the
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only one that can reliably form ascites in a xenograft mouse model within 90 days [32].
OVCAR8 also forms the largest intraperitoneal tumors (1004-1509 mg) by 27 days [32].
Functional characterization in vitro showed that OVCAR8 has the most mesenchymal phenotype
compared to other HGSOC cell lines such as OVCAR5, OVSAHO, SNU119 and CAOV3 [32].
Although, we have gained new insights into the influence of integrin 5 in the context of
EOC, it is vital to continue further experimentation of the results prior to making final
conclusions. My results elucidate that complexity of integrin-mediated cell adhesion interactions
in EOC, since the phenotypes differ across the different cell lines evaluated. By uncovering the
expression of other integrin heterodimers and possible integrin cross talk, future studies may
provide insight into the diversity of integrin function among EOC tumors. Integrins are key
regulators at various steps in the EOC metastatic cascade; therefore, if we can continue to
elucidate potential integrin-mediating signaling mechanisms, it can potentially address the
challenges of using integrin inhibitors as EOC therapeutics currently in clinical trials.
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